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ABSTRACT

ENGINEERING OF POLYAMIDOAMINE (PAMAM) DENDRIMERS
FOR GENE AND DRUG DELIVERY

By Quan Yuan
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy in Biomedical Engineering at Virginia Commonwealth University.

Virginia Commonwealth University, 2012

Major Director: Hu Yang, PhD
Associate Professor, Biomedical Engineering

Dendrimers are a class of polymers with a highly branched, three-dimensional
architecture composed of an initiator core, several interior layers of repeating units and
multiple surface groups. They have been recognized as the most versatile compositionally
and structurally controlled nanoscale building blocks throughout the fields of engineering,
materials science, chemistry, and biology, and they have been widely investigated for
drug and gene delivery. Polyamidoamine (PAMAM) dendrimers have inherent properties
for gene delivery because of their high buffering capacity, polycationic surface and
numerous surface groups for biofunctionlization.
This dissertation is organized into four independent sections. The first section
investigates a series of polyamidoamine-polyethylene glycol-poly (D,L-lactide) (G3.0PEG1500-PDLLA, G3.0-PEG6000-PDLLA, and G3.0-PEG12000-PDLLA) for gene
xii

delivery. Western Blot, fluorescence microscopy and flow cytometry were used as
analysis methods. According to gene transfection studies, G3.0-PEG1500-PDLLA has
been shown to be capable of inducing higher gene expression than the parent dendrimer
compared to unmodified dendrimer, G3.0-PEG6000-PDLLA and G3.0-PEG12000PDLLA.
The second section aims to evaluate an epidermal growth factor (EGF)-containing
PAMAM G4.0 dendrimer vector labeled with quantum dots for targeted imaging and
nucleic acid delivery. Targeting efficiency, cell viability, proliferation, and intracellular
signal transduction were evaluated. We found that EGF-conjugated dendrimers did not
stimulate growth of epidermal growth factor receptor (EGFR)-expressing cells at the
selected concentration. Consistent with this, minimal stimulation of post-receptor
signaling pathways was observed. These nanoparticles can localize within cells that
express the EGFR in a receptor-dependent manner, whereas uptake into cells lacking the
receptor was low. Vimentin short hairpin RNA (shVIM) and yellow fluorescent protein
(YFP) small interfering RNA (siRNA) were used to test the delivery and transfection
efficiency of the constructed targeted vector. Significant knockdown of expression was
observed, indicating that this vector is useful for introduction of nucleic acids or drugs
into cells by a receptor-targeted mechanism.
The third section introduces PEGylated polyamidoamine (PAMAM) dendrimer
G4.0 conjugates with a novel bis-aryl hydrazone (BAH) linkage for gene delivery. It was
found that the incorporation of BAH linkages into the vector significantly enhanced the
buffering capacity of the vector with a high degree of PEGylation. According to gene
transfection studies, this new vector has been shown to be capable of both transfecting

xiii

more cells and inducing higher gene expression than the parent dendrimer. This work
demonstrates that the use of the BAH linkage in coupling of PEG to the dendrimer helps
maintain or increase the buffering capacity of the functionalized dendrimer and results in
enhanced transfection.
In the fourth section, we explored PAMAM dendrimer G4.5 as the underlying
carrier to construct central nervous system (CNS) therapeutic nanoparticles and tested the
buccal mucosa as an alternative absorption site for administration of the dendritic
nanoparticles. Opioid peptide DPDPE was chosen as a model CNS drug. It was coupled
to PAMAM dendrimer G4.5 with PEG or with PEG and transferrin receptor monoclonal
antibody OX26. The therapeutic dendritic nanoparticles labeled with 5-(aminoacetamido)
fluorescein (AAF) or fluorescein isothiocyanate (FITC) were studied for transbuccal
transport using a vertical Franz diffusion cell system mounted with porcine buccal
mucosa. Coadministration of bile salt sodium glycodeoxycholate (NaGDC) or application
of mucoadhesive gelatin/PEG semi-interpenetrating network (sIPN) enhanced the
permeability of dendritic nanoparticles by multiple folds. These results indicate that
transbuccal delivery is a possible route for administration of CNS therapeutic
nanoparticles.
In summary, enhanced nucleic acids delivery by biofunctionalized PAMAM
dendrimers was demonstrated. Transbuccal delivery of CNS therapeutic dendritic
nanoparticles was demonstrated. These vectors will be useful in gene and drug delivery
and could be extended to covalently conjugate other functional moieties for gene and
drug delivery.

xiv

CHAPTER 1 BACKGROUND AND SIGNIFICANCE

1.1

Genes
Deoxyribonucleic acid (DNA) stores genetic information for construction,

development and function of living organisms 1. A DNA molecule consists of two strands,
a coding strand carrying genetic information and a template strand (non-coding strand).
Genes are those DNA segments that carry genetic information. Gene expression is a
process of synthesis of functional gene products such as proteins or functional ribonucleic
acid (RNA). There are several steps involved in the gene expression process including
transcription, translation and post-translational modification. When genes are altered, the
encoded proteins become unable to carry out their normal functions, hence resulting in
genetic disorders.
RNA is essential in converting genetic information from genes into gene products
2

. Three are three major types: messenger RNA (mRNA), ribosomal RNA (rRNA) and

transfer RNA (tRNA). mRNA directs protein synthesis through transcription from a DNA
template in the nucleus, delivery of coding information to ribosomes in the cytoplasm,
and translation into the protein. rRNA is a major component of ribosomes, and it interacts
with tRNA during translation. tRNA carries amino acids used in protein synthesis and
decodes mRNA.

1

Table 1.1
Location
Component (sugar)
Component (bases)
Shape
Major types

1.2

Comparison between DNA and RNA
DNA
RNA
Nucleus
Nucleus and cytoplasm
Sugar is ribose
Sugar is deoxyribose
A, T, C, G
A, U, C, G
Double stranded
Single or double stranded
1 type
3 types: mRNA, tRNA, rRNA

Gene Therapy
Gene therapy is a technique using nucleic acids to treat diseases such as

cardiovascular diseases, infectious diseases, and especially cancers

1,3,4

. There are two

ways to deliver genes: in vivo and ex vivo gene therapy 3. In vivo gene therapy delivers
genetic material to target cells within the body. In contrast, ex vivo gene therapy
genetically modifies target cells extracted from the body, and then the treated cells are
put back in the body. There are several types of genes used in gene therapy: plasmid
DNA, small interfering RNA (siRNA), small hairpin RNA or short hairpin RNA
(shRNA), micro RNA (miRNA) and antisense oligonucleotide 5,6.
A typical plasmid DNA (pDNA) is a circular, double-stranded unit. It
self-replicates within a cell independently of the chromosomal DNA and carries gene
encoding a specific protein. As soon as it is taken up by the nucleus in the cell, it starts
DNA transcription and translation process 5.
siRNA is one of the most potent forms of RNA interference (RNAi) 5-7. RNAi is a
gene therapy method targeting specific genes and down-regulating gene expression.
siRNAs can also bind to specific messenger RNA (mRNA) molecules. The RNAi
pathway is initiated by the ribonuclease protein dicer. Dicer binds to and cleaves long
double-stranded RNA (dsRNA) molecules into short fragments of 20-25 nucleotides.

2

These short double-stranded fragments are called small interfering RNAs (siRNAs). Each
siRNA is unwound into two single strands: the passenger strand and the guide strand. The
guide strand is incorporated into the RNA-induced silencing complex (RISC) and then
pairs with the sequence of the target mRNA molecule, inducing the cleavage of the
mRNA. This cleavage prevents the mRNA from producing protein, thus achieving gene
silencing effects 5-7.
shRNA is another form of RNAi to induce gene silencing 5. It is a sequence of
RNA that makes a tight hairpin turn. It consists of a stem of 25 to 29 bases and a loop of
4 to 23 nucleotides. Following the introduction of shRNA to the cell, its hairpin structure
is cleaved by the enzyme dicer to form siRNA first. The resulting siRNA triggers gene
silence. shRNA plasmid DNA can also be combined with vectors to transfect cells and
produce shRNA in the cell.
miRNA is a short single stranded non-coding RNA with 20-24 nucleotides. It
binds target mRNA at partially complementary sequence sites to gain translational
repression or to disrupt the stability of the target mRNA, hence resulting in gene
silencing effects 5.
Antisense oligonucleotide (AON) is a single strand of DNA or RNA that has a
complementary sequence to a target RNA. Antisense DNA binds to a specific, coding or
non-coding RNA then this DNA/RNA hybrid is degraded by RNase to inhibit gene
expression 2,5.
1.3

Gene Delivery Vectors
Success of gene therapy partially relies on delivery of sufficient therapeutic genes

to target tissues. Gene delivery vectors play an important role in aiding foreign genes to
3

gain entry into somatic cells. Gene delivery vectors are divided into two categories: viral
vectors and non-viral vectors.
1.4

Viral Vectors
Viruses can be used to deliver genetic materials into the cell. Delivery of genes by

a virus is often termed transduction. There are several types of viruses being used as gene
delivery vectors, such as retroviruses, adenoviruses, adeno-associated viruses and Herpes
simplex viruses

8-11

. Viral vectors are highly efficient in gene transfection. However,

safety concerns have restricted their practical applications. Besides, after repeated
administration, viral vectors may induce inflammatory reactions. Furthermore, current
production methods have difficulties producing large quantities of viral vectors for
clinical and commercial applications 8-11.
1.5

Non-Viral Vectors
Synthetic non-viral vectors, particularly cationic polymers, have attracted

considerable attention for gene delivery because of their low toxicity, low
immunogenicity, greater structural flexibility, and cost-effective manufacturing

5,12-14

.

However, their relatively low transfection efficiency has limited their utility. There are
many types of non-viral carriers, such as cationic polymers, liposomes and nanoparticles
12

. To date, no synthetic vectors have successfully overcome all the extra- and

intra-cellular barriers to achieve as high transfection efficiency as viral vectors.
Developing highly efficient synthetic vectors requires identification of essential
properties that synthetic vectors should have for gene delivery.
There are two major types of non-viral vectors for gene delivery: polymer-based
4

vectors and lipid-based vectors

15-19

. For lipid-based vectors, cationic lipids have been

most used for gene delivery 15. Lipoplexes are formed using cationic lipids and negatively
charged DNA by electrostatic interaction. The major mechanism for cellular uptake of
lipoplexes is endocytosis. Cationic lipids have low gene transfection efficiency because
they lack the ability of “endosomal escaping”

15,16

. Some neutral lipids such as

dioleoylphosphatidylethanolamine (DOPE) have been used to form lipoplexes to improve
their transfection efficiency because they can destabilize the endosomal membrane and
help endosomal escaping

20,21

. For polymer-based vectors, cationic polymers have been

the focus for a long time because they can form complexes with DNA

16,18

. The most

frequently studied cationic polymers include dendrimers, polyethyleneimine (PEI),
poly(L-lysine) (PLL) and chitosan 18. However, they all have their own drawbacks so that
they need to be modified to achieve higher gene transfection efficiency or improved
biocompatibility. For instance, chitosan has been used in as a gene vector because of its
good biocompatibility, but its transfection efficiency is still limited due to its low water
solubility or inefficient gene vector unpacking 22,23.
1.6

Administration Strategies for Gene/ Vector Polyplexes
Gene/vector polyplexes can be administered via local delivery and systemic

delivery.
1.6.1

Local Gene Delivery
Local gene delivery methods, such as intratumoral infusion, electroporation, or

implants, provide therapeutic genes directly to the target tissue 24. Local delivery causes
less systemic toxicity in vivo compared to systemic gene delivery. However, the major
5

drawback of this route is invasiveness. Currently the most common method for viral gene
delivery in cancer is intratumoral infusion. Wang et al. 24 studied effects of rate, volume,
and dose of intratumoral infusion on virus dissemination following intratumoral infusion.
They studied an adenoviral vector encoding luciferase in the leg of mice tumor model.
They found that the amount of luciferase expression in the tumor depended on the
infusion dose and volume. They also found the infusion dose determined virus
dissemination. Electroporation uses an externally applied electrical stimulus to increase
the electrical conductivity and permeability of the cell membrane, as a means to introduce
genetic substance such as plasmid DNA into the cell. Wells et al. 25 used electroporation
to enhance gene transfer into murine breast tumors. They transfected MC2 cells using
electroporation or cationic liposomes with pSV-luc plasmids. Most transfected cells were
found in the tumors subjected to electroporation transfection. The results showed that in
vivo electroporation can be used to deliver genes locally to tumors to enhance
transfection. Local gene delivery can also be achieved using implants. Manaka et al.
designed

a

biodegradable

hydrogel,

made

from

26

poly-d,l-lactic

acid-p-dioxanone-polyethylene glycol block co-polymer (PLA-DX-PEG), as an siRNA
carrier. They used the vector to deliver siRNA targeting noggin, an antagonist to bone
morphogenetic proteins (BMPs), and analyzed its gene-silencing efficiency in terms of
ectopic bone formation. They found that adding noggin siRNA to the implant suppressed
noggin expression induced by BMP-2. At the same time, ectopic bone formation treated
with implants containing both BMP-2 and noggin siRNA was significantly higher than
those treated with implants containing BMP-2 alone. The results indicated that the local
delivery of siRNAs by PLA-DX-PEG hydrogel successfully suppressed noggin

6

expression and increased bone-inducing effects of BMP, thus promoting new bone
formation.
1.6.2

Systemic Gene Delivery
Systemic delivery distributes genes complexed with transfection vectors

systemically
delivery

27

27

. Intravenous injection is one of the most common methods of systemic

. In general, gene/vector polyplexes have to circulate in the blood stream

following injection into vasculature. They have to leave the blood vessels, distribute in
the interstitium and then ideally go to the target tissue or cells. However, systemically
administered nucleic acids might encounter barriers that decrease their bioavailability,
such as interactions with blood and endothelial cells, degradation by the liver and
immune responses

27

. Kong et al.

27

modified liposomes with a mannosylated

polyethylene glycol-phosphatidylethanolamine (M-PEG-PE) ligand for targeted gene
delivery. They used rat Kupffer cells to evaluate its in vitro cytotoxicity and transfection
efficiency. They injected the modified liposomes intravenously into the rats for in vivo
gene delivery and expression studies. Their in vitro and in vivo results indicated that the
M-PEG-PE-Lipo-pEGFP complexes showed significantly higher transfection efficiency
than unmodified Lipo-pEGFP. Delgado et al. 28 constructed a gene delivery system using
dextran (Dex), protamine (Prot), and solid lipid nanoparticles (SLN). They used this
vector to deliver pCMS-EGFP plasmid via intravenous administration in mice. Their
results showed that the vector could induce and sustain the expression of the green
fluorescent protein in liver, spleen and lungs, and intra-cellular for at least 7 days.

7

1.7

Barriers to Gene Delivery by Non-Viral Vectors
Even after gene/vector complexes reach the target cell, there are still several

factors present intracellularly affecting gene transfection 5,29: uptake by cells, endocytosis
by endosomes, escape from endosomes/ lysosomes, transport in the cytoplasm,
disassembly of polyplexes, entry to the nucleus, gene transcription in the nucleus and
expression in the cytoplasm.
1.7.1

Cytotoxicity
Cytotoxicity of vectors shall be avoided in gene delivery. Vectors may cause

cytotoxicity in two ways: damaging the cell membrane and causing necrotic cell death
immediately, or disrupting the mitochondrial membrane after internalization and causing
apoptosis in a later stage. For example, polyethyleneimine (PEI) is a polymeric
transfection agent and has been widely used as a gold standard of non-viral vector 7. PEI
has very high gene transfection efficiency but it is highly cytotoxic. Several
biocompatible polymers such as PEG have been used to modify PEI to reduce its
cytotoxicity

30

. For example, Zhang et al.

30

synthesized a series of PEG-PEI with

different molecular weights (MWs) of PEG and degrees of PEGylation. According to
their evaluation of their cytotoxicity to Hela cells, they found that a low level of PEG
grafting to PEI not only reduced its cytotoxicity but also enhanced transfection efficiency.
However, those copolymers with many PEG blocks showed relatively low transfection
efficiency, which might be due to steric hindrance impeding gene entry to the cell.

8

1.7.2

Uptake by Cells
The cell membrane is a lipophilic membrane with embedded proteins that

separates the interior of the cell from the outside. The cell membrane is involved in a
variety of cellular processes such as cell adhesion, cell signaling, etc. The lipophilic cell
membrane with negative charged domains is selectively permeable and serves as a barrier
for uptake of nucleic acids. However, internalization of adequate amounts of nucleic
acids is essential for successful gene delivery and transfection. Therefore, cellular uptake
of genes must be enhanced. Ligands against cell surface receptors can be conjugated to
the vector to increase their uptake. For instance, Yu et al.

31

synthesized epidermal

growth factor (EGF) - polyethylene glycol (PEG)- PAMAM- pentaethylenehexamine
(PEHA) dendron for targeted gene delivery. In their approach, they synthesized
PAMAM-PEHA first and used PEG as a spacer to couple EGF ligand to the conjugate.
They tested transfection efficiency of this vector using HuH-7 hepatocellular carcinoma
cells and compared it with the vector without EGF ligand. The results showed that pDNA
transfections in the group using the vector coupled with EGF ligand had a 10-fold higher
efficiency, thus supporting the concept of ligand targeting for enhancing gene
transfection.
1.7.3

Endosomal Escape
The lack of adequate functions to overcome the post-endocytosis barriers is one of

the major reasons that have made current synthetic vectors far less efficient

32

.

Endocytosis is a process involving multiple steps: binding, internalization, recycle (early
endosomes and recycling endosomes) or degradation (late endosomes and lysosomes).

9

During endocytosis, endosomal escape and subsequent transport of polyplexes through
the cytoplasm before entering the nucleus are two critical steps in the gene transfection
process. After being released from endosomes and lysosomes, DNA is subject to
enzymatic degradation during transport through the cytoplasm due to the presence of
cytosolic nucleases. Slow diffusion leads to excessive enzymatic degradation of DNA in
the cytoplasm, accounting for low gene transfection efficiency. DNA diffusion rate in
cytoplasm decreases dramatically as DNA size increases beyond 1000 base pairs (bp).
DNA of 3000 bp or greater is essentially immobile. Transport of polyplexes in the
cytoplasm is also retarded due to large size. Complete disassembly of polyplexes along
with endosomal escape may be highly demanded for augmentation of gene transfer
efficiency.
The endocytic pathway begins near the physiological pH of 7.4, drops to a lower
pH (5.5-6.0) in endosomes, and approaches pH 5.0 in lysosomes. A number of polymers
have been designed and explored to facilitate intracellular transport of polyplexes by
utilizing the acidic pH gradient. Acid-degradable polycations, such as poly [α-(4aminobutyl)-L-glycolic acid] (PAGA) and poly (β-amino esters), have been designed to
incorporate hydrolytic bonds into the polymer backbone. Those hydrolytic bonds such as
disulphide, acetyl, hydrazone, and ester bonds can break polycations into pieces in the
cytosol and nucleus medium, causing polyplex unpackaging to release free DNA in the
cell. “Proton-sponge” polymers, such as polyamidoamine (PAMAM) dendrimers and PEI,
have been used to facilitate endosomal escape of polyplexes as they contain a large
number of secondary and tertiary amines with a pKa at or below physiological pH. Those
secondary and tertiary amines adsorb the protons released from ATPase and subsequently

10

cause osmotic swelling and rupture of the endosome membrane to release the entrapped
polyplexes.
1.7.4

Entry to Nucleus
The nuclear membrane, also known as the nuclear envelope, is a double lipid

bilayer that serves as a physical barrier to enclose and protect the contents of the nucleus
in eukaryotic cells, similar to the barrier role of a cellular membrane for the cell. In the
nuclear membrane are many nuclear pores that regulate exchange of materials between
the nucleus and the cytoplasm, such as transcription factors and RNA. For siRNA based
RNAi gene therapy, siRNA has to be in the cytoplasm in order to target mRNA. However,
for DNA-based gene therapy, DNA plasmid has to get into the nucleus to provide a
template for mRNA synthesis and protein expression afterwards. Therefore, the nuclear
membrane can be a barrier in gene delivery. The entry of DNA plasmid becomes possible
to the nucleus during the cell division period, when the nuclear envelope disappears.
Therefore, without adding additional functions to the vector, gene plasmids still gain
entry to the nucleus to certain extent for gene transfection.
1.8
1.8.1

Dendrimers
Structure of Dendrimers
Dendrimers are a class of macromolecule with a highly branched,

three-dimensional architecture composed of an initiator core, several interior layers of
repeating units and many surface groups

33-43

. A variety of dendrimers have been

developed using different building blocks, such as PAMAM, polypropylene imine (PPI),
polylysine dendrimers, polyester dendrimers and glycodendrimers.
11

1.8.2

Synthesis of Dendrimers
There are two major approaches to synthesize dendrimers: divergent method and

convergent method 44. In the divergent method, dendrimers are synthesized from the core
as the starting point and built up to the surface groups in the end, while in the convergent
way dendrimers are synthesized from the surface as the starting point and built up to the
core in the end. Because there are many steps involved in the synthesis and because
reactive sites of the dendrimers need to be protected, it is still challenging to synthesize
dendrimers using either method.
Some of the dendrimers are commercially available, such as PAMAM dendrimers
(Aldrich Chemical Company and Dendritech) and PPI dendrimers (Aldrich and DSM
Fine Chemicals), etc. Among them, PAMAM dendrimers are the most well-known and
investigated

41,45

. As a PAMAM dendrimer molecule grows from generation 1 to

generation 10, its size increases from 1.5 to 14.5 nm. The core of PAMAM dendrimer is
usually an ethylenediamine (EDA). It reacts with methyl acrylate and then another
ethylenediamine to yield PAMAM generation 0 (G-0). Higher generations of PAMAM
dendrimers are synthesized based upon more repeated reactions. As generation increases,
the number of surface groups exponentially increases. For example, EDA-core PAMAM
dendrimer generation 2 (G2.0) has 16 surface groups, while PAMAM dendrimer
generation 4 (G4.0) has 64 surface groups and PAMAM dendrimer generation 6 (G6.0)
has 256 surface groups.

12

1.8.3

Properties and Biomedical Uses of Dendrimers
Dendrimers have been recognized as the most versatile compositionally and

structurally controlled nanoscale building blocks throughout the fields of engineering,
materials science, chemistry, and biology 44. They have very low polydispersity and high
functionality. Dendrimers have been investigated in the biomedical field for nano-scaled
drug delivery, gene delivery and imaging contrast agents delivery. The reactive surface
groups of dendrimers can be amino groups, carboxyl groups, hydroxyl groups or a
mixture of these groups

41,45

. They can be conjugated with many types of chemical or

biological molecules such as imaging agents 46, targeting ligands 47, chemical sensors 48,
catalysts

49

, or pharmaceutically active compounds

49,50

. Several dendrimer-based

products have been approved by the FDA for treatment and diagnosis of diseases, such as
VivaGel™ (Starpharma, Melbourne, Australia), SuperFect® (Qiagen, Valencia, CA),
Alert Ticket™(US Army Research Laboratory, Adelphi, MD), and Stratus® CS (Dade
Behring, Deerfield, IL).
1.8.4

Dendrimers for Gene Delivery
Amine-terminated PAMAM dendrimers have been most used for gene delivery

36,51-54

. They have a polycationic nature conferred by the protonated amine surface groups

(pKa=7-9) at physiological pH. Therefore, polycationic dendrimers can form polyplexes
with negatively charged DNA. Structural stability of polyplexes is achieved when the
dendrimer is in excess amounts

7,45

. With the aid of dendrimers, therapeutics can cross

cell membranes or biological barriers. The transport of PAMAM dendrimers and
surface-modified PAMAM dendrimers across cell monolayer generally follows

13

endocytosis-mediated cellular internalization

55-57

. The overall positive charge of the

polyplex allows interaction with negatively-charged cell surface domains. This
interaction results in adsorptive endocytosis and/or membrane destabilization. Thus, the
nucleic acids complexed with the dendrimer can be efficiently internalized. Following
internalization, the inner core of polycationic dendrimers can act as a “proton-sponge” to
facilitate the escape of polyplexes from endosomes and lysosomes

55,56,58,59

. Once

entrapped in endosome or lysosome, protonation of the amines results in an influx of
counter ions and a significant increase in the osmotic pressure. Osmotic swelling causes
rupture of the endosomal or lysosomal membrane releasing the polyplexes into the
cytoplasm. The polyplex then travels in the cytoplasm by diffusion to the nucleus for
gene expression. Although the mechanism of gene transfection of dendrimers has been
explored for a long time, the precise mechanism remains to be elucidated.
Dendrimers have been further functionalized to improve their performance as
gene vectors. Qi et al.

53

used PEG with a molecular weight of 5,000 to modify G5 and

G6 PAMAM dendrimers (PEG-PAMAM) at three different molar ratios of 4%, 8%, and
15% (PEG to surface amine per PAMAM dendrimer molecule). The results showed that
PEGylation, especially at higher degrees, significantly decreased cytotoxicity of G5 and
G6 dendrimers in vitro and in vivo compared with unmodified PAMAM dendrimers.
Among all of the PEG-PAMAM dendrimer conjugates, 8% PEG-conjugated G5 and G6
dendrimers resulted in the most efficient transfection in vivo and in vitro.
Choi et al.

60

conjugated arginine to the surface of G4 PAMAM dendrimers. The

pendant arginine molecules were included to mimic the TAT peptide for cell membrane
penetration. They tested its transfection efficiency in HepG2, Neuro2A, and primary rat
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aorta smooth muscle (SMC) cells. The results showed that dendrimers with arginine
modification were more efficient than unmodified dendrimers due to their membrane
penetrating ability. Yu et al.

52

introduced histidine residues into arginine grafted

PAMAM G4 dendrimers. The results showed that conjugation of histidine residues into
PAMAM G4-arginine improved their proton buffering capacity and its transfection
efficiency was improved considerably with the increase in the number of histidine
residues on the dendrimer surface.
Ma et al. 54 used triamcinolone acetonide (TA), one of the glucocorticoid steroids,
to modify PAMAM dendrimers to enhance translocation of pDNA into the nucleus. It
was reported that binding of glucocorticoid steroid to its receptor can dilate the nuclear
pore complexes, facilitating the transport of plasmid DNA (pDNA) into the nucleus more
easily. Their results showed that the transfection efficiency of luciferase and enhanced
green fluorescent protein (EGFP) genes by PAMAM-TA was greater than native
PAMAM in HEK 293 and HepG 2 cells. In addition, confocal microscopy examination
confirmed that PAMAM-TA conjugate may assist in the translocation of the polyplex to
the nucleus.
Dendrimer vectors have been used to deliver genes to treat diseases in various
organs, such as skin, brain, breast, prostate, etc. Kwon et al.

61

used an arginine-grafted

cationic dendrimer, PAM-RG4 to combine with plasmid DNA encoding vascular
endothelial growth factor (VEGF) and injected them subcutaneously into diabetic mice.
Healing of topical skin wounds in the diabetic mice within 6 days after injection was
confirmed by appearance of wound closure and histological analysis. In another study,
Kim et al.

62

used PAMAM dendrimer to deliver high mobility group box 1 (HMGB1)

15

siRNA intranasally in the postischemic rat brain. They found this gene delivery method
markedly suppressed infarct volume in the postischemic rat brain. Xin et al.

63

generation

antisense

4

polyamidoamine

(G4PAMAM)

dendrimer/COX-2

used a

oligodeoxynucleotide complex (G4PAMAM/COX-2ASODN) and investigated their
effects on the tumor tissues of nude mice with breast cancer. Following the treatment, the
COX-2 mRNA level and protein expression in the tumor tissue were decreased markedly.
So was microvessel density (MVD) in the tumor tissue. As a result, tumor growth was
restrained. Chen et al. 64 used generation 5 PAMAM dendrimers to combine with suicide
gene system and anti-tumor drug gemcitabine and treat nude mice with prostate tumor.
They found that this new suicide gene system mediated by G5-PAMAM-D is effective in
inhibiting tumor growth in vivo. Liu et al.

65

designed PAMAM dendrimers bearing a

triethanolamine (TEA) core. In vitro studies showed that these dendrimers can form
stable nanoparticles with DNA and improve cell uptake in epithelial and fibroblast cells
as well as gene transfection efficiency. More impressively, in vivo studies confirmed their
efficient transfection in the mouse thymus.
1.8.5

Dendrimers for Drug Delivery
Dendrimers were used for drug delivery as anti-cancer, anti-inflammatory or

anti-thrombotic therapy. A summary of dendrimers for drug delivery were listed in table
1.2.
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Table 1.2

Dendrimers for drug delivery

(Reprinted and adapted from 66 with permission from Springer)
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2.1

Hypothesis and Specific Aims
We have developed novel dendritic polyethylene glycol-poly(D, L-lactide)

(PEG-PDLLA) nanoparticles for drug delivery. They consist of a PAMAM dendrimer
G3.0 as the core and clustered PEG-PDLLA chains on the surface. We found in aqueous
solution, they can self-assemble into sub-micron/micron aggregates, whose size is
dependent on temperature and PEG-PDLLA chain length as well as displays reversibility
upon temperature variation. These nanoparticles are expected to have increased fusogenic
potential for enhanced nucleic acid uptake owing to their hydrophobic blocks. We
hypothesize that dendrimer-PEG-PDLLA will have enhanced gene transfection
efficiency compared to the parent dendrimer after its surface modification.
To test the above hypotheses, we propose three specific aims in this section
follows:
Specific Aim 1: Characterize this gene delivery system based on PAMAM-PEG-PDLLA;
Specific Aim 2: Assess efficacy of the gene delivery system in vitro;
Specific Aim 3: Elucidate their structure-function (i.e., gene transfection activity)
relationships.
2.2

Abstract
A series of dendritic PEG-PDLLA (G3.0-PEG1500-PDLLA, G3.0-PEG6000-

PDLLA, and G3.0-PEG12000-PDLLA) were synthesized and evaluated as new gene
delivery vectors. The synthesis involved two sequential steps: conjugation of PEG to the
dendrimer and ring-opening polymerization of D, L-lactide. 293T cells were used to
evaluate the cytotoxicity and gene transfection efficiency of the synthesized dendritic

19

PEG-PDLLA. Western Blot, fluorescence microscopy and flow cytometry were used as
analysis methods. Dynamic light scattering was used to characterize the dendritic
PEG-PDLLA nanoparticles. According to gene transfection studies based on 293T cells,
G3.0-PEG1500-PDLLA has been shown to be capable of both transfecting more cells
and inducing higher gene expression than the parent dendrimer. It also shows that
G3.0-PEG6000-PDLLA and G3.0-PEG12000-PDLLA barely improve the gene
transfection efficiency compared to unmodified dendrimer. G3.0-PEG1500-PDLLA is
particularly useful in gene delivery and could be extended to covalently conjugate other
functional moieties for enhanced gene delivery.
2.3

Introduction
Dendrimers are composed of an initiator core, several interior layers composed of

repeating units, and multiple active surface groups that enable a high drug payload and/or
assembly of a variety of functional moieties

45,56,67-69

. They have been considered as the

most versatile nanostructured platform for drug and gene delivery

29

. Among them,

Polyamidoamine (PAMAM) dendrimers appear to be an ideal class of building blocks for
developing gene delivery system because of their well-defined globular highly branched
architecture and unique properties

69

. Covalent coupling of functional groups to the

PAMAM dendrimer is a viable approach to develop therapeutic modalities for drug or
gene delivery

35,70

. One thrust of the dendrimer-based applications is to explore

amine-terminated PAMAM dendrimers as non-viral vector for gene delivery

29

.

Amine-terminated PAMAM dendrimers can efficiently complex with nucleic acids to
form polyplexes through electrostatic interactions, protect them from enzymatic
degradation, and enable their efficient cellular uptake. Further, many tertiary amines
20

present in the branches confer the dendrimer high buffering capacity, which facilitates the
endosomal escape of polyplexes—a barrier for release of nucleic acid into the cytoplasm.
Because of their adaptable structures, dendritic vectors have capability of evolving into
multifunctional vectors, thus offering advantages over linear polymeric vectors for gene
transfer.
PAMAM dendrimer-based targeted gene delivery is being actively studied to
increase targeting specificity, elevate transfection efficiency, and reduce systemic toxicity.
Functionalizing dendrimers through the modification of the periphery of dendrimers with
various moieties remains a mainstream approach to modulating the properties of
dendrimers for efficient gene transfection. For instance, epidermal growth factor receptor
(EGFR) is overexpressed in many types of cancers such as head and neck cancer, breast
cancer, etc. and can be targeted for receptor-mediated delivery. Ligand against EGF
receptor such as EGF can be coupled to the PAMAM dendrimer surface to direct
dendrimer vector/nucleic acid polyplexes to EGFR-expressing cells

35

. Because of high

expression levels of folate receptors in certain types of cancers, folic acid has been
coupled to the dendrimer to enable efficient gene targeting to tumors. Delivery of
therapeutic antisense oligonucleotides to C6 glioma cells by folate-PAMAM dendrimer
conjugates resulted in suppression of EGFR expression and cell growth 71. To fully utilize
the multivalency of dendrimers, conjugation of polyethylene glycol (PEG), peptides, and
other functional moieties to the dendrimer surface have also been studied to confer new
features to the vector for enhanced gene delivery 36,70. PEGylation of PAMAM dendrimer
via bis-aryl hydrazone linkage has been shown to increase the buffering capacity of the
dendrimer. As a result, the increase in percentage of transfected cells and quantity of gene
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expression product has been observed

36

. Recently, hydrophobic chains coupled to the

dendrimer have been shown to facilitate the cellular uptake of polyplexes of dendritic
vector/nucleic acid, owing to their specific lipophilic interactions with the lipid cell
membrane

72

. Poly (D, L-lactide-co-glycolide) (PLGA), polyethylene glycol (PEG) and

poly (D, L-lactide) (PDLLA) polymers are biocompatible and biodegradable polymers.
They have been used in gene transfection because of their low cytotoxicity and
immunogenicity 73-76.
We have developed novel dendritic polyethylene glycol-poly(D, L-lactide)
(PEG-PDLLA) nanoparticles, which consist of a PAMAM dendrimer G3.0
macromolecule as the underlying core and clustered PEG-PDLLA chains on the surface
with hydrophobic PDLLA blocks being the outmost layer 40. Dendritic PEG-PDLLA (i.e.,
DPP) nanoparticles show low toxicity. Interestingly, in aqueous solution, they can
self-assemble into sub-micron/micron aggregates, whose size is dependent on
temperature and PEG-PDLLA chain length as well as displays reversibility upon
temperature variation. DPP nanoparticles are expected to have increased fusogenic
potential for enhanced nucleic acid uptake owing to their hydrophobic blocks. As they
possess unique architectural features and properties that may be desirable in gene
delivery, the ability of DPP nanoparticles to transfect cells was examined and the
elucidation of their structure-function (i.e., gene transfection activity) relationships was
attempted in this work.
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2.4
2.4.1

Materials and Methods
Materials
Polyamidoamine (PAMAM) dendrimer generation 3.0 was purchased from

Dendritech (Midland, MI). PEG diol (molecular weight 1500, 6000 or 12,000 g mol-1),
DLLA (6-dimethyl-1,4-dioxane-2.5-dione), tin(II) 2-ethylhexanoate (stannous octoate,
SnOct2), ninhydrin, chloroform, tetrahydrofuran (THF), 4-nitrophenyl chloroformate
(4-NPC), triethylamine (TEA), ethyl ether (anhydrous), N,N-dimethylformamide (DMF),
dichloromethane (DCM), ethanol (denatured), MTT

(3-(4,5-dimethylthiazol-2-yl)- 2,5-

diphenyltetrazolium bromide) and branched PEI (MW=25,000 gmol-1) were purchased
from Sigma-Aldrich (St. Louis, MO). TransIT keratinocyte transfection reagent (referred
to as TransIT) was obtained from Mirus Bio (Madison, WI). pBMN-I-GFP plasmid was a
gift from Dr. Garry Nolan, Stanford University.77 pMAX-GFP plasmid was purchased
from Lonza (Gaithersburg, MD). Anti-GFP (B-2) and anti-actin (sc-1616) antibodies
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Horseradish
peroxidase conjugated goat anti-mouse and rabbit anti-goat secondary antibodies were
purchased from MP Biomedicals (Solon, OH). Dulbecco’s modified Eagle medium
(DMEM) and fetal bovine serum (FBS) were purchased from Invitrogen (Carlsbad, CA).
Polyvinylidene difluoride (PVDF) membrane (Immobilon-P) was purchased from
Millipore (Billerica, MA). Western Lightning ECL was purchased from Perkin Elmer
(Waltham, MA).
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2.4.2

Synthesis of Dendritic PEG-PDLLA (DPP) Core-Shell Nanoparticles
The synthesis followed our previously reported procedure and reaction conditions

78

. Basically, it involved two sequential steps: coupling of PEG diol (1500, 6000 or

12,000 g mol-1) to PAMAM dendrimer G3.0 and ring-opening polymerization of D,
L-lactide through the hydroxyl end groups of PEG chains. The resultant DPP-#
nanoparticles (# = 1500, 6000, or 12000, denoting the molecular weight of PEG coupled
to the dendrimer), namely DPP-1500, DPP-6000, and DPP-12000, were evaluated in
gene transfection studies.
2.4.3

Cell Culture
Human kidney 293T cell line (ATCC, Manassas, VA) cell line 36 was used in this

work. They were maintained at 37˚C in a humidified atmosphere containing 10% CO2
and 90% air in growth medium composed of DMEM supplemented with 10% fetal
bovine serum (FBS) and penicillin-streptomycin (100 units/ml).
2.4.4

In vitro Transfection
293T cells were seeded in 6-well plates at a density of 5×104 cells/well and

allowed to grow in 2 ml of growth medium containing 10% FBS for 24 hours prior to
transfection. The cells were then transfected with the polyplexes of DPP/GFP plasmid
(50, 100, or 200 µg/1 µg), PEI/GFP plasmid (20 µg/1 µg), and TransIT/GFP plasmid (5
µl/1 µg) prepared in 100 µl of serum-free DMEM medium for 6 hours. After that, the
medium in each well was replaced with 2 ml of fresh growth medium containing 10%
FBS. The cells were further incubated for 48 h and then subjected to various bioassays.
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2.4.5

Post-transfection Cytotoxicity Assay
To determine the toxicity of DPP during transfection studies, 293T cells were

cultured and treated with plain vectors under the same condition as used in gene
transfection. At 48 h post-transfection, cell viability was determined in triplicate using the
MTT assay. Briefly, after in vitro gene transfection, cells were incubated with 0.1 vol of
5mg/ml 3-[4,5-dimethylthiazol-2-yl]- 2,5-diphenyl tetrazolium bromide (MTT reagent;
Sigma, St. Louis, MO) in media for 4h at 37 °C to enable formation of formazan crystals.
The reagent and media were then removed and crystals solubilized with 1mL of MTT
solubilization buffer (10% SDS in 0.01M HCl) for 16h at 37°C. The absorbance was then
determined spectrophotometrically at 570 nm.
2.4.6

Size Measurement
The mean particle sizes of DPP alone and DPP/GFP plasmid polyplexes at a ratio

of 200: 1 were measured at 25 ºC and 37 ºC using a Malvern Zetasizer Nono S (Malvern
Instruments, Malvern, UK). Three identical sample solutions were prepared for each
measurement. Light scattering intensity was recorded and scatter intensities were plotted
as Zimm plots to calculate the mean particle size and size distribution (i.e. polydispersity
index with a value between 0 and 1).
2.4.7

Fluorescence Microscopy
True-color fluorescent images of the cells transfected with pMAX-GFP plasmid

were taken using a Zeiss Axiovert 200 inverted fluorescence microscope (Carl Zeiss
Microimaging, Thornwood, NY).
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2.4.8

Flow Cytometry Analysis
Following the removal of the growth medium, transfected cells were washed

twice with ice-cold DPBS and re-suspended using trypsin for 5-10 min. The cells were
fixed with cold 70% ethanol for 1 hour at 4 ºC, centrifuged and washed with DPBS, and
then transferred to microcentrifuge tubes containing 500 µl of PBS. Afterwards, the cells
were incubated with 1µg/ml RNase for 1 h at room temperature and stained with
propidium iodide (50 µg/mL). The cells were then analyzed by using a Guava EasyCyte
mini flow cytometry system (Millipore, Billerica, MA).
2.4.9

Western Blot
After the growth medium was removed, cells were washed twice with ice-cold

DPBS and lysed on ice for 10 minutes using 60 µl of cell lysis buffer (20 mM HEPES,
pH 7.5, 10 mM EGTA, pH8.0, 40mM β-glycerophosphate, 1% NP-40, 2.5 mM MgCl2,
20 µg/ml aprotinin, 20 µg/ml leupeptin, 1 mM PMSF), scraped immediately, and
transferred to sterile 1.5 ml microcentrifuge tubes. Supernatant was transferred to a fresh
microcentrifuge tube after 10 min of microcentrifugation at 10,000 g at 4 °C. Cleared
lysates were quantified using a modified Bradford assay (BCA; Biorad, Hercules, CA),
and equivalent amounts of protein were resolved by SDS-PAGE and then transferred to
polyvinylidene difluoride (PVDF) membrane (Immobilon-P; Millipore, Billerica, MA).
Membranes were blocked in 5% skim milk in TTBS (10 mM Tris-HCl, pH 7.6, 0.5%
Tween-20, 150 mM NaCl) for 1 h at room temperature, and then incubated in primary
antibodies diluted 1:1000 in blocking buffer overnight at 4 °C. After washing in TTBS,
bound primary antibodies were detected using horseradish peroxidase conjugated
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secondary antibodies and Western Lightning Enhanced Chemiluminescence (ECL;
Perkin-Elmer, Waltham, MA).
2.4.10

Intracellular Trafficking Studies
293T cells were seeded on borosilicate glass coverslips in 6-well plates at a

density of 5 × 104 cells/well and allowed to grow in 2 mL of growth medium containing
10% FBS for 24 h. The cells were incubated with the polyplexes of G3.0-PEG1500PDLLA or G3.0 (control)/Label IT Cy3 plasmid (50 µg/0.5 µg in 100µL of serum-free
DMEM medium) for various lengths of time (i.e., 1 h, 3 h, 6 h and 24 h). Quantitative
uptake of Label IT Cy3 Plasmid/ dendrimer G3.0 and Label IT Cy3 Plasmid/dendrimerPEG1500-PDLLA uptake by 293T cells at various time points was assessed by flow
cytometry.
2.4.11

Statistical Analysis
Data were analyzed with analysis of variance (ANOVA) followed by Holm-Sidak

method for pairwise comparison of subgroups using SigmaPlot 12 (Systat Software Inc.,
San Jose, CA). P values <0.05 were considered statistically significant.
2.5
2.5.1

Results and Discussion
Synthesis of Dendritic PEG-PDLLA Conjugates
The structure and compositions of dendritic PEG-PDLLA nanoparticles were

confirmed and characterized by the ninhydrin assay, 1H-NMR, Fourier transform infrared
spectroscopy, dynamic light scattering and atomic force microscopy in our previous work
40

.
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2.5.2

Cytotoxicity
Potential toxicity of dendritic PEG-PDLLA and control vectors-TransIT-

keratinocyte transfection reagent, PEI, and unmodified PAMAM dendrimer G3.0— used
to complex with DNA was examined under the gene transfection conditions employed in
this work. TransIT-keratinocyte transfection reagent (TransIT) is a commercially
available transfection reagent with low cellular toxicity and high transfection efficiency.
PEI (25 kDa) is considered as a gold standard in gene transfection but it has high cellular
toxicity. Both TransIT and PEI were used as controls along with unmodified PAMAM
dendrimer G3.0 in this work. To avoid its significant dose-induced toxicity during gene
transfection, the amount of PEI used to complex with GFP plasmid was purposely kept
low (i.e., 20:1 for vector/plasmid). As shown in Figure 2.1, TransIT showed negligible
cytotoxic effects to 293T cells; however, PEI was found to be most toxic among the
control groups, reducing cell viability to 22%. Unmodified PAMAM dendrimer G3.0
showed cytotoxic effects to a certain extent. Its toxicity was dose-dependent as the cells
incubated with PAMAM dendrimer G3.0 at 200:1 had the lowest cell viability (i.e., 80%).
293T cells incubated with various amounts of DPP-1500, 6000, and 12000 used in gene
transfection maintained invariably high viability, suggesting high cytocompatibility of
dendritic PEG-PDLLA.
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Cell viability of 293T cells post-transfection, as determined by the MTT

293T cells were seeded in 6-well plates at 5×104 cells/well, cultured for 24 h,
incubated with PEI (20 µg), TransIT (5 µl), PAMAM dendrimer G3.0 (50, 100, and
200 µg), and DPPs (50, 100, and 200 µg) for 6 h, rinsed, and then cultured for another
48 h. # indicates no significant difference.

2.5.3

In vitro Transfection Studies
293T cell line was used to evaluate in vitro gene transfection efficiency of

dendritic PEG–PDLLA, and GFP plasmid was used as a reporter gene. The transfection
efficiency of dendritic PEG–PDLLA was evaluated in terms of GFP expression, which
was qualitatively illustrated by fluorescence images and quantified by both flow
cytometry and western blot.
The fluorescence images of GFP-expressing 293T cells are shown in Fig.2.2. It is
obvious that PEI-mediated gene transfer resulted in a stronger fluorescence signal in
transfected cells than TransIT-mediated gene transfer. Visual comparison of the cells
transfected by PAMAM dendrimer G3.0 and PAMAM G3.0 coupled with PEG-PDLLA
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(DPP-1500, DPP-6000, and DPP-2000) revealed that DPP-1500 was able to induce most
GFP expression and that GFP expression was enhanced by increasing vector to plasmid
ratio. However, DPP-6000 and DPP-12000 did not show improved GFP expression as
compared to the modified dendrimer.

Figure 2.2 Representative fluorescence images of 293T cells transfected with GFP
plasmid mediated with different vectors. (×100).
293T cells were seeded in 6-well plates at 5×104 cells/well, cultured for 24 h,
incubated with 1 µg GFP plasmid complexed with PEI (20 µg), TransIT (5 µl),
PAMAM dendrimer G3.0 (50, 100, and 200 µg), and DPPs (50, 100, and 200 µg) for 6
h, rinsed, and then cultured for another 48 h.
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Flow cytometry analysis (Fig. 2.3.) revealed that the proportion of GFPexpressing 293T cells was 25.5% by PEI and 6.5% by TransIT. Although it was logical to
expect that higher ratio of vector to plasmid would achieve higher transfection efficiency,
the change of vector to plasmid ratio from 50:1, 100:1, to 200:1 did not increase fraction
of GFP-expressing 293T cells. This held true for the cells transfected by unmodified
PAMAM G3.0 and dendritic PEG-PDLLA particles. Both unmodified PAMAM
dendrimer G3.0 and DPP-1500 had the same efficiency transfecting cells. Further
statistical analysis of DPP-1500, 6000, and 12000 disclosed that DPP-1500 was able to
transfect most cells, whereas DPP-6000 had least transfection efficiency in terms of

Percentage of GFP expressing cells (%)

percentage of GFP-expressing cells.
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Percentage of GFP-expressing 293T cells.

293T cells were seeded in 6-well plates at 5×104 cells/well, cultured for 24 h,
incubated with 1 µg GFP plasmid complexed with PEI (20 µg), TransIT (5 µl),
PAMAM dendrimer G3.0 (50, 100, and 200 µg), and DPPs (50, 100, and 200 µg) for 6
h, rinsed, and then cultured for another 48 h. The cells were then subjected to flow
cytometry analysis. Untreated cells were used as a negative control. # indicates no
significant difference.
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Given that DPP-1500-mediated gene transfection resulted in a similar level of
GFP-expressing cells to the unmodified dendrimer, these two vectors were further
compared in terms of actual amount of GFP product resulting from gene transfection. To
this end, western blotting (Fig. 2.4.) was used to quantify the levels of GFP expression in
the transfected cells. PEI and TransIT showed high transfection efficiency. The levels of
GFP expression induced by PEI and TransIT were 6.6-fold and 3.9-fold higher than
PAMAM dendrimer G3.0, respectively. Again, increasing vector to plasmid ratio from
100:1 to 200:1 for PAMAM dendrimer G3.0 and DPP-1500 did not induce more GFP
expression in 293T cells. However, the DPP-1500-mediated gene transfer significantly
increased GFP expression in 293T cells by nearly 100% as compared to G3.0-medidated
gene transfer.
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Quantification of GFP expression in 293T cells

293T cells were seeded in 6-well plates at 5×104 cells/well, cultured for 24 h,
incubated with 1 µg GFP plasmid complexed with PEI (20 µg), TransIT (5 µl),
PAMAM dendrimer G3.0 (50, 100, and 200 µg), and DPPs (50, 100, and 200 µg) for 6
h, rinsed, and then cultured for another 48 h. The cells were then subjected to western
blotting. Untreated cells were used as a negative control. GFP expression bands (top)
was quantified by using Quantity One (Bio-Rad) and normalized to actin of each
group (bottom). # indicates no significant difference.
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2.5.4

Intracellular Trafficking Studies
Quantification of Cy3-labeled plasmid uptake by 293T cells showed that both

PAMAM dendrimer G3.0 and DPP-1500 were able to deliver a similar amount of
plasmid to the cell during 6 h-incubation. Although DPP-1500 and unmodified PAMAM
dendrimer G3.0 transfected similar fractions of 293T cells, DPP-1500 induced GFP
expression twice as high as GFP expression induced by G3.0 and was nontoxic during
transfection. Therefore, DPP-1500 improved gene transfection efficiency and

Cellular uptake of Cy3-labeled plasmid (%)

cytocompatibility of unmodified PAMAM dendrimer G3.0.
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Cellular uptake of Cy3-labeled plasmid by 293T cells.

293T cells were incubated with Cy3-labeled plasmid alone (0.5 μg) or polyplexes of
DPP-1500 or G3.0/Label IT Cy3 plasmid (50 μg/0.5 μg) for 6 h and then subjected to
flow cytometry analysis. # indicates no significant difference.
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2.5.5

Size Measurement
In this work, we explored the application of DPP as a gene delivery vector and

examined the effect of chain length of PEG-PDLLA coupled to the dendrimer on gene
complexation and the size of polyplexes. A saturated PEG-PDLLA layer was created on
the surface of PAMAM dendrimer G3.0. Consistent with our previous work, DPP-1500,
6000, and 12000 formed large aggregates of sub/microns on the respective order of 200,
500, and 1000 nm at 25 °C in aqueous solution, and those aggregates gained a 3-4 fold
increase in size when temperature was increased to 37 °C (Fig. 2.6). The change of
particle size of DPP aggregates was negligibly affected following complexation with
GFP plasmid at a DPP to DNA ratio of 200:1 (the highest ratio employed in gene
transfection studies). However, the size of DPP/GFP polyplexes increased by 3-4 folds
with temperature increase, regardless of PEG-PDLLA chain length. This result indicated
that complexation of DPP with DNA plasmid did not interfere DPP’s self-assembly
process in aqueous solutions. Because of a dense polymer layer and self-assembly of DPP
into larger particles, the formation of DPP/DNA plasmid polyplexes was achieved more
likely via encapsulation of DNA by the DPP aggregates aided with longer range forces29
instead of direct binding of DPP to DNA. Therefore, the delivery vector in this case was
DPP aggregates, the size of which falls into the microscale.
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Figure 2.6 Particle sizes of DPPs and DPP/GFP plasmid polyplexes at 25 ˚C and 37
˚C determined by dynamic light scattering.
2.6

Discussion
Gene transfection can be influenced by encapsulation efficiency of the vector and

cellular uptake of polyplexes

79

. Although molecular mechanisms with which particles

enter the cell have yet to be fully elucidated, more studies support cellular uptake of
particles via endocytosis such as phagocytosis, macropinocytosis, clathrin-mediated
endocytosis, and non-clathrin-mediated endocytosis. In general, hydrophobic blocks on
the nanoparticles would help increase fusogenic potential of the vector for enhanced
nucleic acid uptake. However, in endocytosis, particle size plays an important role in
determining which cellular pathway and processing shall be taken 79,80. It is reported that
cellular uptake of ligand-devoid particles with a size greater than 1 µm is low

79

. Since

the sizes of both DPP-6000 and DPP-12000 at 37 °C exceeded a threshold value of 1 µm,
reduced cellular uptake of particles was presumably responsible for low uptake of
35

plasmid and hence gene expression. We also noticed that although the fractions of
transfected cells by DPP-6000 and DPP-12000 were much lower than those of transfected
cells by G3.0 and DPP-1500, DPP-12000 could transfected more cells than DPP-6000
likely due to its fusogenic potential being enhanced by a longer hydrophobic PDLLA
block.
We found that PAMAM dendrimer G3.0 and DPP-1500 had a similar efficiency
in carrying GFP plasmid to the cell and transfecting cells. However, GFP expression was
increased by 100% with the application of DPP-1500 as opposed to PAMAM dendrimer
G3.0. We attributed this enhanced gene expression to accelerated dissociation of plasmid
from the polyplexes as a result of hydrolysis of the ester linkages in PDLLA and
disruption of DPP aggregates. Particularly, following endosomal entrapment, clustered
dendrimer molecules in the DPP vector would exert the proton sponge effect to rupture
the endosomal membrane and the lowering of the internal pH to about 5.5 during
endosome maturation can break up ester bonds to destabilize the vector, thus causing
endosomal escape of polyplexes as well as release of plasmids from the DPP vector.
Taken together, our studies suggest that gene transfection efficiency of dendritic
PEG-PDLLA nanoparticles is size-dependent. The gene transfection studies based on
293T cells showed that PAMAM dendrimer G3.0 fully conjugated with PEG
1500-PDLLA (i.e., DPP-1500) is able to transfect a similar fraction of 293T cells as
unmodified PAMAM dendrimer G3.0 but induce a higher level of GFP expression. In
contrast, PAMAM dendrimer G3.0-coupled with longer chains, i.e., PEG6000-PDLLA
and PEG12000-PDLLA, failed to achieve improved gene transfection efficiency. The
current work demonstrated that the chain length of PEG-PDLLA on the dendrimer and
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the size of the self-assembled of DPP aggregates significantly impact the vector’s gene
transfection efficiency.
Dendritic PEG-PDLLA with a size smaller than 1 µm can be used for enhanced
gene delivery. Further optimization is still needed as DPP-1500 transfection efficiency
was still lower than PEI and TransIT. Because PAMAM dendrimers possess a high
payload of functional groups on the surface, couple ligands to the dendrimer surface can
help improve cellular uptake via receptor-mediated endocytosis. In addition, modulating
degree of dendrimer surface modification with PEG-PDLLA, the composition of
PEG-PDLLA, and fine-tuning size of DPP particles through structural modification or
temperature variation will be studied in future work to further reveal structure-function
(i.e. gene transfection) relationships of dendritic PEG-PDLLA as gene vector.
2.7

Conclusions
Dendritic PEG–PDLLAs with various chain lengths were prepared using

PAMAM dendrimer G3.0 as the underlying carrier and evaluated for gene delivery.
Dendritic PEG-PDLLAs possessed improved cytocompatibility. Gene delivery efficiency
of DPP vectors was found to be dependent on PEG-PDLLA length and particle size of
resulting aggregates. Improved gene transfection was observed when the dendrimer
surface was modified with PEG1500-PDLLA. This work demonstrated that structurally
optimal dendritic PEG-PDLLA can be used as a new vector for gene delivery to achieve
higher transfection efficiency than the unmodified PAMAM dendrimer.
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3.1

Hypothesis and Specific Aims
Epidermal growth factor receptor (EGFR) regulates cell growth, survival,

differentiation, and motility in vivo. It is over-expressed in multiple human solid tumors,
including tumors of brain, lung, breast and colon. EGF and anti-EGFR antibody have
been used as targeting ligands to selectively enhance cellular uptake of drugs or gene
delivery systems by tumors. We hypothesize that EGFR-targeted dendrimer
conjugates will target EGFR expressing cells with specificity, as they overexpress
the EGFR at the cell surface.
To test the above hypotheses, we propose three specific aims in this section as
follows:
Specific Aim 1: Design, synthesize and characterize a novel EGFR-targeted nucleic acid
delivery system based on PAMAM dendrimer;
Specific Aim 2: Evaluate EGFR targeting ability, cell proliferation, and signal pathway
activation of the delivery system in vitro;
Specific Aim 3: Assess efficacy of the nucleic acid delivery system in vitro.
3.2

Abstract
We designed an epidermal growth factor (EGF)-containing polyamidoamine

(PAMAM) Generation 4 dendrimer vector labeled with quantum dots for targeted
imaging and nucleic acid delivery. 1H-NMR, SDS-PAGE, and Western blotting were
applied to characterize the synthesized G4.0-GGG-EGF nanoparticles. Targeting
efficiency, cell viability, proliferation, and intracellular signal transduction were
evaluated using HN12, NIH3T3, and NIH3T3/EGFR cells. We found that
39

EGF-conjugated dendrimers did not stimulate growth of EGFR-expressing cells at the
selected concentration. Consistent with this, minimal stimulation of post-receptor
signaling pathways was observed. These nanoparticles can localize within cells that
express the EGFR in a receptor-dependent manner, whereas uptake into cells lacking the
receptor was low. A well characterized vimentin shRNA (shVIM) and yellow fluorescent
protein (YFP) siRNA were used to test the delivery and transfection efficiency of the
constructed targeted vector. Significant knockdown of expression was observed,
indicating that this vector is useful for introduction of nucleic acids or drugs into cells by
a receptor-targeted mechanism.
3.3

Introduction
Dendrimers have emerged as the most versatile nanostructured platform for drug

delivery because of their well-defined highly branched architecture and numerous surface
sites that enable a high drug payload and/or assembly of a variety of functional moieties
45,81

. Polycationic dendrimers have been extensively studied for gene delivery because

they aid efficient internalization of DNA following endocytosis and membrane
destabilization, and facilitate the escape of gene/dendrimer polyplexes from endosomes
and lysosomes as a result of their well-known proton-sponge feature

29,82-88

. Covalent

coupling of targeting ligands to the dendrimer is a viable approach to develop efficient
targeted therapeutic modalities for drug delivery. Epidermal growth factor receptor
(EGFR) overexpression occurs in multiple human solid tumors, including cancers of the
head and neck, lung, breast, colon, and brain

89,90

. EGF

89

and anti-EGFR antibody such

as Cetuximab 91 have been used as targeting ligand to selectively enhance cellular uptake
of drug-carrying vehicles by human carcinomas.
40

EGFR signaling regulates cell growth, survival, differentiation, and motility.
Since EGFR-targeted drug delivery systems possibly utilize the ligand-receptor
interaction for drug delivery, it is important to determine the cellular response to EGFR
ligation by targeted nanoconjugates, to ensure that stimulation of pro-oncogenic
properties does not occur. To date, considerable attention has been paid to confirmation
of the enhanced uptake of ligand-carrying dendrimers by cells. Nonetheless, subsequent
intracellular signal transduction mediated by EGF-conjugated dendrimers and impact on
therapeutic efficacy has not been well studied. One report indicated the possibility that
use of EGF-conjugated nanoparticles may enhance cell growth

89

whereas, in another

study, the authors reported a synergistic growth inhibitory effect on EGFRoverexpressing

breast

cancer

cells

by

EGF-conjugated

poly(ε-caprolactone) block copolymer loaded with ellipticine

92

polyethylene

glycol-

. It should also be noted

that, while the normal response of keratinocytes to EGF is proliferation, many tumor cells
do not display this and may even be growth-inhibited by EGF 93. Thus, biochemical and
biological effects may vary, depending upon the reagent used and the nature of the target
cell, and should be considered in design of EGFR-targeted vectors. In this study, the
synthesis and characterization of EGF-conjugated dendrimers are discussed.
3.4
3.4.1

Materials and Methods
Materials
Polyamidoamine (PAMAM) dendrimer generation 4.0, triglycine (GGG),

N-hydroxysuccinimide

(NHS),

1-ethyl-3-[3-dimethylaminopropyl]

carbodiimide

hydrochloride (EDC), N,N'-disuccinimidyl carbonate (DSC), and triethylamine (TEA)
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and vimentin antibody were purchased from Sigma-Aldrich (St. Louis, MO).
Recombinant human epidermal growth factor (EGF) was purchased from Austral
Biologicals (San Ramon, CA). Antibodies that recognize EGFR (sc-03), ERK2 (sc-54),
p-ERK (sc-101760), phosphotyrosine (sc-508), GFP (sc-9996), and actin (sc-1616) were
purchased from Santa Cruz Biotechnologies Inc. (Santa Cruz, CA). Anti-p-AKT (4058)
was obtained from Cell Signaling Technology (Danvers, MA). Anti-AKT1 (559028) was
purchased from BD Biosciences Pharmingen (Mississauga, ON Canada). Horseradish
peroxidase-conjugated secondary antibodies were obtained from MP Biomedical (Aurora,
OH). Qdot® 525 ITK™ amino (PEG) quantum dots were purchased from Invitrogen
(Carlsbad, CA). TransIT keratinocyte transfection reagent was obtained from Mirus Bio
(Madison, WI). siRNA targeting yellow fluorescent protein (YFP) was purchased from
Qiagen (Valencia, CA).
3.4.2

Synthesis of EGF-Conjugated Dendrimer Derivatives
As illustrated in Fig. 3.1, the synthesis of EGF-conjugated dendrimers involves

two steps—introducing a triglycine spacer to the dendrimer, and coupling EGF to the
dendrimer via the spacer.
Step 1: Introducing triglycine spacer to the dendrimer. Triglycine was activated
into an active ester by using NHS/EDC in

0.1M sodium phosphate buffer (pH 5.5),

where the feed molar ratio of triglycine: NHS: EDC was 1:1.2:1.2

94

. The resulting

N-hydroxysuccinimide (NHS)-activated triglycine (i.e., NHS-GGG) was slowly added to
the G4.0 PAMAM dendrimer-containing biocarbonate buffer solution (pH 8.5) and the
reaction proceeded for 2 hours, where the feed molar ratio of NHS-GGG-NH2/G4.0 was
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64:1. After reaction, the resultant G4.0-GGG was purified by dialysis against deionized
water and then lyophilized.
Step 2: Coupling EGF to G4.0-GGG. Recombinant human EGF was activated
using NHS/EDC for 15 minutes with a feed molar ratio of 1:2:3 for EGF: NHS: EDC in
0.1M sodium phosphate buffer (pH=5.5). Afterward, G4.0-GGG-NH2 was slowly added
to the solution for an overnight coupling reaction at ambient temperature, where the feed
molar ratio of EGF to G4.0-GGG-NH2 was 5:1. The resulting G4.0-GGG-EGF was
ultrafiltered four times using a Centriprep® centrifugal filter unit (30,000 NMWL)
(Nominal Molecular Weight Limit), (Millipore, Billerica, MA) and then lyophilized.

Figure 3.1

Synthetic schemes of EGF-triglycine-dendrimer conjugates

3.4.3

Labeling Dendrimers with Quantum Dots (Qdots)
Qdots were linked to the dendrimer via a long PEG spacer to minimize

interference of fluorophores with assembled functional entities on the dendrimer surface.
As shown in Fig. 3.2, Qdot® 525 ITK™ amino (PEG) quantum dots were coupled to the
dendrimer via triglycine using a DSC/TEA coupling method

95

, where the feed molar

ratio of Qdot to G4.0 PAMAM was 1:1. Briefly, Qdots (1 equivalent) dissolved in DMF
were activated by adding DSC (1 equivalent) and TEA (1 equivalent). After an overnight
reaction with stirring, the resulting Qdot-NHS was then precipitated with cold ether and
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vacuum dried. A 2h coupling reaction between Qdot-NHS esters and G4.0-GGG-EGF (1
equivalent) was carried out in a pH 8.5 biocarbonate buffer solution. The resulting Qdot
-labeled G4.0 nanoparticles were purified by dialysis against deionized water and
lyophilized.

Figure 3.2 Synthetic schemes of labeling EGF-triglycine-dendrimer conjugates
with Qdots coated with amine-derivatized PEG
1

3.4.4
1

H-NMR Spectroscopy

H-NMR spectra of the synthesized polymers were recorded on a Varian

superconducting Fourier-transform NMR spectrometer (Mercury-300). Deuterium oxide
(D2O, 99.9%) was used as the solvent. The chemical shift for D2O is 4.8 ppm.
3.4.5

SDS-PAGE Assay
SDS polyacrylamide gel electrophoresis was carried out by standard procedures.

For analysis of dendrimer derivatives, 12% resolving gels were used and subsequently
stained overnight in 0.25% Coomassie R250 dye, destained, fixed and dried for analysis.
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3.4.6

Cell Culture
Culture conditions for HN12, HN13, NIH3T3 and NIH3T3/EGFR cells have

been described previously

96-99

. Briefly, HN12 and HN13 cells were maintained in

Dulbeccos’s modification of Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 100 units/mL penicillin, and 100 µg/mL streptomycin at 37 °C in a
humidified atmosphere containing 10% CO2, and 90% air. NIH3T3 and NIH3T3/EGFR
cells were maintained in DMEM with 10% bovine calf serum.
3.4.7

Immunostaining
Immunofluorescent detection of cellular proteins was carried out as previously

described 100. Briefly, cell lines were plated on sterilized round cover slips in twelve well
plates and incubated for 24 h allowing attachment. Then the cells were serum starved for
24h, washed with PBS, and fixed with cold methanol at -20ºC (on ice) for 20min. The
cells were washed with PBS for 5 min, and blocked in 5% BSA, 0.1% Triton-X 100 in
PBS on top of soaked filter paper for 1h at room temperature. After 1h blocking, the cells
were incubated with 200uL of monoclonal antibody diluted 1:250 in blocking buffer
overnight at 4ºC wrapped with parafilm. The cells were then washed five times with PBS
for 5 min, and incubated with secondary FITC conjugated anti-mouse antibody at 1:500
dilution in 5% BSA, 0.1% Triton-X 100 in PBS for 1h at room temperature covered with
foil. Cells were washed five times with PBS for 5 min, and plated on microscope slides
with 1 drop of Vectashield (Vector Laboratories, Burlingame, CA) and observed under a
Zeiss Axiovert 200 inverted fluorescence microscope.
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3.4.8

Cell Proliferation Assays
Measurement of cell growth was carried out by MTT assay and by cell counting

assays, as described previously

101

. Briefly, cells were seeded in triplicate at a density of

5×103 cells per well in 12-well tissue culture plates and allowed to attach and proliferate
for 24 h in complete medium (DMEM containing serum), and another 24 h in serum-free
medium. Cells were cultured with different treatments (10 ng/ml EGF, G4.0-GGG-EGF
[equimolar with respect to EGF] or an equimolar amount of G4.0-GGG) for 5 days and
incubated with 0.1 vol of 5mg/ml 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
bromide (MTT reagent; Sigma, St. Louis, MO) in media for 4h at 37 °C to enable
formation of formazan crystals. The reagent and media were then removed and crystals
solubilized with 1mL of MTT solubilization buffer (10% SDS in 0.01M HCl) for 16h at
37°C. The absorbance was then determined spectrophotometrically at 570 nm.
Alternatively, cells (2×103 cells/well) were seeded in triplicate in five 12 well tissue
culture plates. The cells were allowed to attach and proliferate for 24 h in complete
medium (DMEM containing 10% FBS), after which the medium was replaced with
serum-free medium for 24 h. Cells were treated for 3 days with EGF, non-EGF
conjugated dendrimer (G4.0-GGG), or EGF-conjugated dendrimer (G4.0-GGG-EGF).
Cultures were trypsinized and counted daily.
3.4.9

Western Blot Analysis
Western blotting of total cellular protein was carried out by standard procedures,

as described previously

93

. Briefly, Cultures at 50% confluence were washed twice in

ice-cold PBS, and lysed in 50 mM Hepes pH 7.5, 150 mM NaCl, 1mM EDTA, 0.1%

46

Tween-20, 1mM PMSF, 20 µg/mL aprotinin, and 20 µg/mL leupeptin, on ice for 10 min,
scraped immediately, and transferred to sterile 1.5 mL microcentrifuge tubes. Supernatant
was transferred to a fresh microcentrifuge tube after 10 min of microcentrifugation at
10,000 g at 4°C. Cleared lysates were quantified using a modified Bradford assay (BCA;
Bio-Rad, Hercules, CA), and equivalents amounts of protein were resolved by
SDS-PAGE and then transferred to polyvinylidene difluoride (PVDF) membrane
(Immobilon-P; Millipore, Billerica, MA). Membranes were blocked in 5% skimmed milk
in TTBS (10 mM Tris-HCl, pH 7.6, 0.5% Tween-20, 150 mM NaCl) for 1 h at room
temperature, then incubated in primary antibodies diluted 1:1000 in blocking buffer
overnight at 4°C. After washing in TTBS, bound primary antibodies were detected using
horseradish peroxidase-conjugated secondary antibodies (MP Biomedicals, Solon, OH)
and ECL Western Lightning (Perkin Elmer Inc., Waltham, MA).
3.4.10

Nucleic Acid Delivery
HN12 cells or YFP-expressing HN12 cells were seeded in six-well culture plates

and allowed to proliferate until 40% confluent. To prepare vector/DNA complexes, 5 µg
of G4-GGG-EGF, G4, or 2 µL of TransIT were mixed with 2 µg of shVIM plasmid DNA
or YFP siRNA in 50 µL H2O, gently vortexed and allowed to stand at room temperature
for 20 min. The solution was centrifuged briefly, plated in duplicate wells, and incubated
for 48 h. Vimentin or YFP expression was quantified by Western blot.
3.4.11

Statistical Analysis
All statistical analysis was based on a Kruskal–Wallis one way ANOVA on ranks

and a Tukey–Kramer pairwise multiple comparison procedure (α = 0.05) performed with
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the JMP®Pro 10.0.0 statistical software package (SAS Institute, Inc.). Graphical
depictions of mean data were constructed with Microsoft Excel 2000, with error bars
representing standard deviations.
3.5

Results and Discussion

3.5.1

Structural Characterization of EGF-Conjugated Dendrimer Derivatives
Spectroscopic and bioanalytical assays were applied to characterize dendrimer

derivatives. According to the 1H-NMR spectrum shown in Fig. 3.3., nearly 64 triglycine
spacer molecules were conjugated to the dendrimer surface, indicating 100% surface site
modification.

Figure 3.3

1

H-NMR (D2O) spectrum of G4.0-GGG conjugates

SDS-PAGE analysis further confirmed that the surface sites were completely
modified with triglycine. As shown in Fig. 3.4., the major band (solid arrowhead) of
G4.0-GGG conjugates falls into the range of 25-37 kDa, as predicted for G4.0 carrying
64 triglycine spacer molecules. In addition, two bands (open arrowheads) above 50 kDa
are attributed to the aggregation of G4.0-GGG conjugates.
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Figure 3.4

SDS-PAGE analysis of PAMAM dendrimer conjugates

G4.0-GGG conjugates were applied to a 12% SDS–polyacrylamide gel, resolved and
stained with Coomassie R-250. Molecular size markers are indicated.
Previously, glutaric anhydride was utilized as a spacer between EGF and
dendrimer, which introduced negatively charged carboxylate groups to the dendrimer
surface

96-99

. Although this may not be a concern for delivery of drugs through covalent

conjugation, the reduction of amine surface groups will diminish the ability of
dendrimer-based vectors to complex with nucleic acids, which is based on electrostatic
interaction, hence our use of triglycine. The C-terminus of triglycine was used for
conjugation with G4.0 PAMAM dendrimers, making available the N-terminus for
subsequent coupling with EGF and Qdots, and maintaining sufficient numbers of amine
groups on the dendrimer for complexation with nucleic acids.
Purity of G4.0-GGG-EGF conjugates was assessed by Western blot, which also
indicated the molecular weight of G4.0-GGG-EGF conjugates and the number of EGF
moieties per dendrimer, together with the 1H-NMR and SDS-PAGE results. Based on
molecular size, it was found that G4.0-GGG-EGF conjugates had an average of one EGF
molecule per dendrimer according to our Western blot assay (Fig. 3.5). These results also
demonstrated

that

the

chemical

synthesis
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was

robust.

Multiple

batches

of

G4.0-GGG-EGF were synthesized. As shown in Fig. 3.5., no detectable free EGF band
was found in the purified product obtained from two different syntheses, indicating its
suitability for use in subsequent studies of cell growth and signal transduction.

Figure 3.5

Western blot analysis of G4.0-GGG-EGF dendrimers

G4.0-GGG-EGF nanoparticles were electrophoresed, together with the indicated
amounts of recombinant EGF standards, then Western blotted and probed with
anti-EGF antibody. #1, first synthesis; #2, second synthesis.
3.5.2

Targeting Ability of Qdot-Labeled EGF-Conjugated Dendrimers
Overexpression of epidermal growth factor receptor (EGFR) occurs in up to

80%- 90% of HNSCC, of which the EGFR is 38%- 47% overexpressed compared to
normal cells

102,103

. To examine EGFR expression prior to study of targeting ability of

EGF-conjugated dendrimers, immunostaining was performed. NIH3T3 fibroblasts
express low levels of EGFR, which is shown by immunostaining (Fig. 3.6.A.). In contrast,
NIH3T3/EGFR cells showed high expression of EGFR at the cell membrane (Fig. 3.6.B.).
The EGFR is mostly localized at the cell surface, but is also internalized into endosomes
after ligand binding. EGFR was also found in the cytoplasm and nucleus in the HN12
cells, but with strong immunoreactivity predominantly in the cell membrane (Fig. 3.6.C.).
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The levels of EGFR in these cell lines indicate their suitability for use in our study. Since
both NIH3T3/EGFR and HN12 cells express a high level of EGFR, we used them to
evaluate the biological properties of the delivery system in order to ascertain its
generality in interacting with EGFR-expressing cell lines.

Figure 3.6 EGFR immunostaining. NIH3T3 cells (A), NIH3T3/EGFR (B) and
HN12 (C) (x630)
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Fluorophores such as FITC can be directly conjugated to amine-terminated
dendrimers to facilitate visualization

104

. Indeed, we have already prepared FITC-labeled

dendrimers and evaluated toxicity and cellular uptake. However, photostability and
loading density cannot be controlled well due to the presence of many reactive end
groups on the dendrimer surface. Since our G4.0-GGG-EGF conjugates are intended for
gene delivery, direct coupling of fluorophores to the dendrimer may impair the ability of
dendrimer to complex with nucleic acids. Therefore, we used Qdots to provide long-term
photostability to EGF-conjugated dendrimers, which can be potentially used for targeted
live-cell imaging and dynamics studies

105,106

. According to our previous report,

N-terminal conjugation of triglycine to G4.0 significantly reduced dendrimer toxicity 43.
Here, the number of amine surface groups remained unchanged after C-terminal
triglycine conjugation. The toxicity of G4.0 modified with triglycine was similar to that
of unmodified G4.0. Because of the negligible toxicity of dendrimers at concentrations of
0.2 µM or below as identified, we evaluated the synthesized conjugates at or below 0.2
µM to exclude potential toxic effects.
Receptor-mediated uptake of EGF-conjugated dendrimers was demonstrated
using HN12 and NIH3T3/EGFR cells, using Qdot-labeled dendrimer-EGF conjugates.
We chose the concentration of EGF from our previous studies which is optimal for
inducing a downstream signaling response in the cells used

93,107

. As shown in Fig. 3.7,

EGF-conjugated dendrimers were efficiently taken up into EGFR-expressing cells,
whereas uptake by NIH3T3 controls was minimal.
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Figure 3.7 EGFR-dependent uptake of Qdot-labeled PAMAM dendrimer G4.0
derivatives (x400)
NIH3T3/EGFR cells, or NIH3T3 as control, were exposed to G4.0-GGG-EGF
nanoparticles for 24 h, then fixed, counterstained with DAPI and imaged as described
in Methods.
Further experiments compared the effect of the EGF moiety on internalization.
NIH3T3/EGFR cells were incubated in the presence of Qdot-G4.0-GGG-EGF, or
Qdot-G4.0-GGG and Fig. 3.8 shows that Qdot-labeled EGF-conjugated dendrimers are
detectable in NIH3T3/EGFR cells within 1 h, and this becomes more profound with a
longer incubation period (14 h). In contrast, uptake of Qdot-labeled dendrimers lacking
EGF is minimal.
Similar data were obtained with HN12 cells (Fig. 3.9). These data suggest that
EGF-conjugated dendrimers can be taken up efficiently by cells in an EGFR-dependent
manner. In addition, the contrast between EGFR-positive and -negative cells strongly
indicates that the EGF conjugated to the nanoparticles is active in terms of receptor
binding ability. Since EGF retained its targeting ability after conjugation, the chemistry
employed was satisfactory.
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Figure 3.8 EGFR-dependent uptake of Qdot-labeled PAMAM dendrimer G4.0
derivatives by NIH3T3/ EGFR cells (x400).
NIH3T3/EGFR cells were exposed to Qdot-G4.0-GGG (Q-G4) or QdotG4.0-GGG-EGF (Q-G4-E) nanoparticles for the indicated times, then processed as in
(A).
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Figure 3.9 EGFR-dependent uptake of Qdot-labeled PAMAM dendrimer G4.0
derivatives by HN12 cells (x400)
HN12 cells were exposed to Qdot-G4.0-GGG (Q-G4) or Qdot-G4.0-GGG-EGF
(Q-G4-E) nanoparticles for the indicated times, then processed as in (A).
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3.5.3

Effect of EGF-Conjugated Dendrimers on Cell Proliferation
As EGF can be a potent mitogen for normal and some transformed epithelial cells,

we determined the effect of EGF-conjugated dendrimers on cell proliferation. Cells were
seeded in 12-well culture plates, serum-starved and then exposed to equimolar amounts
of G4.0-GGG, G4.0-GGG-EGF, or EGF as control. After three days, viability was
determined by MTT assay. Fig. 3.10 shows combined results from four experiments run
in triplicate using HN12 cells. No significant difference was observed between cells
treated with EGF-conjugated or -unconjugated dendrimers (p = 0.62-0.99).

Figure 3.10

MTT assay of HN12 cells treated with nanoparticles

HN12 cells were cultured in triplicate in the presence of the indicated compounds and
the number of viable cells determined by MTT assay. Bar = SD.
3.5.4

Post-Receptor Signaling Events
To determine possible biochemical events that occur in cells exposed to

EGF-conjugated dendrimers, we treated HN12 cells as above, prepared protein lysates
and Western blotted these with antibodies that recognize phosphorylated (active) forms
of ERK and AKT, protein kinases that are activated in a wide range of cells following
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EGFR ligation. Robust phosphorylation (activation) of ERK was found in EGF-treated
cells, as predicted (Fig. 3.11), whereas the EGF-conjugated dendrimer induced minimal
ERK activation.

Figure 3.11

Western blot of HN12 cells treated with nanoparticles

HN12 cells were serum starved, then treated with G4.0-GGG, G4.0-GGG-EGF, or
EGF as a control for 10 minutes. Total cellular protein lysates were prepared and
Western blotted with the indicated antibodies.
Similar observations were made in NIH3T3/EGFR cells (Fig. 3.12). Taken
together, these data suggest that the EGF-conjugated dendrimers used in these studies do
not activate common proliferation-associated signaling pathways in EGFR-expressing
cells, consistent with the results of cell growth assays.
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Figure 3.12 Western blot of NIH3T3 and NIH3T3/EGFR cells treated with
nanoparticles
Both cell lines were serum starved, then treated with G4.0-GGG, G4.0-GGG-EGF, or
EGF as a control for 10 minutes. Total cellular protein lysates were prepared and
Western blotted with the indicated antibodies.
3.5.5

Nucleic Acid Delivery
The efficiency of EGF-conjugated dendrimers to deliver nucleic acids was tested

by examining RNA interference-mediated vimentin knockdown and YFP. To exclude
any potential interference of Qdots with nucleic acid delivery, EGF-conjugated
dendrimers without Qdots were used. A previously used vimentin shRNA (shVIM)
plasmid

100

or YFP siRNA were used to transiently transfect HN12 cells or

YFP-expressing HN12 cells, respectively. As indicated in Fig. 3.13.A, vimentin
expression was moderately reduced by 20% or 23% in HN12 cells treated with shVIM
delivered by unconjugated dendrimer or TransIT. However, a significant 40% reduction
in vimentin expression was found in HN12 cells transfected with shVIM delivered by
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EGF-conjugated dendrimers (Fig. 3.13.A). A significant reduction (70%) of YFP
expression mediated by G4.0-GGG-EGF delivery of siRNA was observed in HN12/ YFP
cells (Fig. 3.13.B). This confirms enhanced nucleic acid delivery by EGF-conjugated
dendrimers and suggests that EGFR-targeted delivery may be a viable approach for
efficient delivery of nucleic acids such as shRNA plasmids and siRNA.

Figure 3.13 RNAi-mediated gene knockdown using EGF-conjugated dendrimers.
(A) Vimentin expression, (B) YFP expression.
(A) HN12 cells plated in six-well plates at 40% confluence were treated with 2 µg of
shVIM plasmid DNA complexed with G4.0-GGG-EGF (5 µg), G4.0 (5 µg), TransIT
(2 µL), or untreated. Vimentin expression was quantified by using Quantity One
(Bio-Rad) and normalized to actin of each group. Vimentin expression was expressed
with the level in untreated cells being 100%. (B) YFP-expressing HN12 cells plated in
six-well plates at 40% confluence were untreated, treated with 2 µg of YFP siRNA
complexed with 2 µL of TransIT, 5 µg of G4.0, or 5 µg of G4.0-GGG-EGF. Proteins
were extracted, Western blotted with the indicated antibodies and YFP expression
calculated relative to actin as an internal standard. # indicates significant differences
from G4.0-GGG-EGF group compared with other groups.
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3.6

Conclusions
We have developed EGF-conjugated dendrimer nanoparticles, using a triglycine

spacer for conjugation of EGF. These nanoparticles were further labeled with Qdots to
afford a targeted imaging modality. They localized intracellularly in an EGFR-dependent
manner, whereas uptake into cells lacking the receptor was low. EGF-conjugated
dendrimers did not stimulate growth of EGFR-expressing cells and minimal stimulation
of post-receptor signaling pathways was observed. The efficiency of the constructed
targeted delivery system was demonstrated through the delivery of vimentin shRNA
plasmid and YFP siRNA. The data indicate that this may be a useful nanoscale vector for
introduction of nucleic acids or drugs into cells by a growth factor-targeted mechanism,
and for targeted cell imaging.
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4.1

Hypothesis and Specific Aims
Amine-terminated PAMAM dendrimers has been used widely for gene delivery.

Owing to the large buffering capacity conferred by a number of primary surface amines
and tertiary amines inside the core, PAMAM dendrimers can act as a “proton-sponge” to
facilitate the escape of polyplexes from endosomes or lysosomes in an acidic
environment. The bis-aryl hydrazone (BAH) linkage contains a protonatable pyridine and
two protonatable amines. The use of this linkage will provide an additional site for
protonation, making it possible to enhance the buffering capacity of the vector even with
a high degree of surface modification. We hypothesize that dendrimer conjugates with
BAH linkages will have enhanced buffering capacity and increased gene
transfection efficiency compared to the parent dendrimer.
To test the above hypotheses, we propose three specific aims in this section as
follows:
Specific Aim 1: Design, synthesize and characterize a gene delivery system based on
PAMAM dendrimer;
Specific Aim 2: Evaluate the buffering capacity of the gene delivery system;
Specific Aim 3: Assess efficacy of the gene delivery system in vitro.
4.2

Abstract
Surface

modification

of

polyamidoamine

(PAMAM)

dendrimers

with

polyethylene glycol (PEG) often results in the decrease in their buffering capacity, which
is essential for gene transfer. In this work, bis-aryl hydrazone bond, which possesses
protonatable pyridine and amines, was explored as a new linkage for PEGylation of
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PAMAM dendrimers. PEGylated polyamidoamine (PAMAM) dendrimer G4.0
conjugates with bis-aryl hydrazone (BAH) linkages were synthesized following a
two-step procedure: activation of PAMAM dendrimer G4.0 and monofunctional
methoxypolyethylene

glycol

amine

(MW=5000

Da)

with

succinimidyl

4-hydrazinonicotinate acetone hydrazone (SANH) and succinimidyl 4-formylbenzoate
(SFB), respectively, and coupling of SFB-activated PEG to SANH-activated G4.0 to
generate PEGylated G4.0 with bis-aryl hydrazone linkages (G4.0-BAH-PEG). It was
found that the incorporation of BAH linkages into the vector significantly enhanced the
buffering capacity of the vector even with a high degree of PEGylation (42 PEG chains
per dendrimer). G4.0-BAH-PEG conjugates could complex with DNA plasmid tightly at
low weight ratios and display dramatically improved cytocompatibility. According to
gene transfection studies in 293T and HN12 cells, this new vector has been shown to be
capable of both transfecting more cells and inducing higher gene expression than the
parent dendrimer. This work demonstrates that the use of the BAH linkage in coupling of
PEG to the dendrimer helps maintain or increase the buffering capacity of the
functionalized dendrimer and results in enhanced transfection.
4.3

Introduction
Synthetic non-viral vectors, particularly cationic polymers, have attracted

considerable attention for gene transfer as they can potentially avoid toxicity and
immunogenicity, provide high DNA carrying capacity, achieve prolonged gene
expression, and allow low-cost manufacturing

108-112

. However, the lack of adequate

functions to overcome multiple extra- and intra-cellular barriers is the major reason why
synthetic vectors are far less efficient than viral vectors and have limited clinical utility to
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date. The evolving understanding of potential barriers to gene delivery, for example
polyplex unpackaging

113,114

, has led to development of a number of synthetic vectors

having various functionalities to improve gene transfection efficiency. Developing
multifunctional non-viral vectors has become an important goal in order to endow them
with transfection efficiency approaching that of viral vectors.
Amine-terminated polyamidoamine (PAMAM) dendrimers appear to be an ideal
class of building blocks for developing multifunctional vectors, not only because of their
well-defined highly branched structures and a number of surface groups available for
assembly of many different types of functional entities, but because of a number of
inherent properties desirable for gene delivery

82-88,115-118

. Polycationic dendrimers can

stably form polyplexes with nucleic acids and facilitate their efficient internalization,
mainly through endocytosis. The endocytic pathway begins near the physiological pH of
7.4, drops to a lower pH (5.5-6.0) in endosomes, and approaches pH 5.0 in lysosomes 119.
Owing to the large buffering capacity conferred by a number of primary surface amines
and tertiary amines inside the core, dendrimers can act as a “proton-sponge” to facilitate
the escape of polyplexes from endosomes or lysosomes in an acidic environment 111.
In addition to the extensive use of commercially available PAMAM dendrimers, a
number of new or engineered PAMAM dendritic structures, such as PEGylated PAMAM
dendrimers, reducible hyperbranched poly(amidoamine)s with disulfide bonds
polycationic PAMAM esters with grafted arginines
new core

122,123

121

120

,

, and PAMAM dendrimers with a

, have been developed for enhanced gene transfection. PAMAM

dendrimers with polyethylene glycol (PEG) arms, namely PEGylated PAMAM
dendrimers, are a group of dendrimer derivatives that have important biomedical and
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pharmaceutical applications

124

. The incorporation of PEG chains into the dendritic

structure can yield a number of biologically and pharmacokinetically desirable properties
such as improved biocompatibility, reduced immunogenicity, prolonged half-life,
increased water solubility, and enhanced structural stability, as reported in previous work
41,78,125-129

. The use of PEGylated PAMAM dendrimers for gene transfection has been

demonstrated. Luo et al. conjugated PEG to PAMAM dendrimer generation 5 (G5.0) via
a stable amide linkage and observed its high efficiency in transfecting Chinese hamster
ovarian cells

130

. Recent work by Qi et al. revealed that the degree of PEGylation is an

important variable affecting the transfection efficiency of PEGylated PAMAM
dendrimers
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PAMAM-PEG

. PAMAM-block-PEG-block-PAMAM
125

131

and transferrin- coupled

have also been developed to enhance transfection efficiency and

specificity, respectively.
Because of the occupancy of the primary surface amine groups, surface
modification of amine-terminated dendrimers by PEG potentially impairs the buffering
capacity of the modified dendrimer, which, in turn, may result in unsatisfactory
transfection efficiency

111

. To ensure high transfection efficiency, high weight ratios of

vector to plasmid are therefore needed, for example 250-1200:1 (w/w) for PAMAM
dendrimer G5.0 conjugated with 14 PEG chains (MW=3400 gmol-1) through amide
bonds

130

. Although a viable approach is to minimize the degree of dendrimer surface

modification, this strategy becomes questionable, particularly when a high degree of
PEGylation is needed in order to keep the vector nontoxic for a long term and/or when
the assembly of more functional groups is necessary for making the vector
multifunctional. Therefore, the linkages connecting PEG or other moieties to the
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dendrimer are preferably not to compromise with the buffering capacity of the
constructed vector. The impaired buffering capacity of dendritic vectors by the surface
modification has not been addressed before. To this end, we employed a stable bis-aryl
hydrazone (BAH) linkage for coupling of PEG to the dendrimer. The BAH linkage
contains a protonatable pyridine and two protonatable amines

132

, the use of this new

linkage not only compensates for the loss of surface amines due to modification but
provides an additional site for protonation, making it possible to enhance the buffering
capacity of the vector even with a high degree of surface modification. In this work, PEG
chains were grafted to PAMAM dendrimer G4.0 via bis-aryl hydrazone linkages. The
fundamental aspects of the constructed PEGylated PAMAM dendrimers having bis-aryl
hydrazone linkages including synthesis, characterization, and transfection efficiency were
examined.
4.4
4.4.1

Materials and Methods
Materials
Polyamidoamine (PAMAM) dendrimer ([Core: ethylene diamine (EDA)]; [G=4];

[dendri-poly(amidoamine)-(NH2)64]) was purchased from Dendritech (Midland, MI).
Succinimidyl 4-hydrazinonicotinate acetone hydrazone (SANH) and succinimidyl
4-formylbenzoate (SFB) were purchased from Pierce (Rockford, IL). Monofunctional
methoxypolyethylene glycol amine (NH2-PEG-OCH3, MW=5000 gmol-1) and PEI
(25,000 gmol-1) were purchased from Sigma-Aldrich (St. Louis, MO). TransIT
keratinocyte transfection reagent (referred to as TransIT) was obtained from Mirus Bio
(Madison, WI). pBMN-I-GFP plasmid was A gift from Dr. Garry Nolan, Stanford
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University

77

. pMAX-GFP plasmid was purchased from Lonza (Gaithersburg, MD).

Anti-GFP (B-2) and anti-actin (sc-1616) antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Horseradish peroxidase conjugated goat anti-mouse
and rabbit anti-goat secondary antibodies were purchased from MP Biomedicals (Solon,
OH). Dulbecco’s modified Eagle medium (DMEM) and fetal bovine serum (FBS) were
purchased from Invitrogen (Carlsbad, CA). TransIT keratinocyte transfection reagent
(referred to as TransIT) and Label IT® Cy3™ Plasmid Delivery Control (red) were
purchased from Mirus Bio (Madison, WI). Polyvinylidene difluoride (PVDF) membrane
(Immobilon-P) was purchased from Millipore (Billerica, MA). Western Lightning ECL
was purchased from Perkin Elmer (Waltham, MA).
4.4.2

Synthesis of PEGylated PAMAM Dendrimers with Bis-Aryl Hydrazone
Linkages
As illustrated in Fig. 4.1., the synthesis involves two steps—activation of

PAMAM dendrimer G4.0 and NH2-PEG-OCH3 (MW=5000 gmol-1) with SANH and SFB,
respectively, and a subsequent coupling reaction between SANH-modified G4.0 and
SFB-modified PEG. To modify G4.0 with SANH, 4.1 µmol of SANH in 2 ml of DMF
was added to 2 ml of modification buffer (100 mM phosphate, pH 7.4) containing 0.085
µmol of PAMAM dendrimer G4.0. The reaction mixture was stirred for 6 hours. To
modify NH2-PEG-OCH3 with SFB, 2 ml of DMF containing 4.1 µmol SFB was slowly
added to 2 ml of modification buffer, in which 4.1 µmol of NH2-PEG-CH3 was dissolved.
The reaction proceeded for 6 hours. Once the modification of NH2-PEG-OCH3 and G4.0
was complete, the solutions containing SANH-modified G4.0 and SFB-modified PEG
were mixed, where the molar ratio of SFB-modified PEG to SANH-modified G4.0 was
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varied in order to obtain different degrees of PEGylation on the dendrimer surface. The
reaction was allowed to proceed overnight while stirring. The resultant G4.0 tethered
with 42 PEG chains via bis-aryl hydrazone linkages (referred to as G4.0-BAH-PEG42)
was purified by dialysis against deionized water and then freeze-dried. Following the
same chemistry, G4.0 tethered with 3 PEG chains via bis-aryl hydrazone linkages (i.e.,
G4.0-BAH-PEG3) was also obtained.

Figure 4.1

Synthesis of G4.0-BAH-PEG conjugates.

4.4.3

1

1

H-NMR Spectroscopy

H-NMR spectra were recorded on a Varian superconducting Fourier-transform

NMR spectrometer (Mercury-300). Deuterium oxide (D2O, 99.9%) was used as the
solvent. The chemical shift for D2O residue is 4.8 ppm.
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4.4.4

Acid-Base Titration Assay
Each dendrimer sample (2.5 mg) was dissolved in 5 mL of 0.1M NaCl solution.

The solution was adjusted to pH 9.0 with 0.1M NaOH and then titrated by adding small
aliquots (25 µl, 10 µl, or 5 µl) of 0.1 M HCl until pH 4.0 was reached. The pH value was
monitored using a pH meter. Buffering capacity of a vector is defined as follows:
Buffering capacity =NExperimental/NTheoretical/M, where NExperimental is the experimental moles
of titrant added to buffer solution over pH change, NTheoretical is the theoretical change in
moles of H+ over the same pH change, and M is molarity. The pH change from 5.5 to 6.0,
which mimics the acidic environment in late endosomes 133, was used for the calculation.
4.4.5

Gel Retardation Assay
The formation of G4.0-BAH-PEG/DNA polyplexes was examined by

electrophoretic mobility in an agarose gel. The polyplexes were formed by mixing
dendrimer vector with 1 µg of GFP plasmid at different weight ratios ranging from 0 to
40 in 50 µl of Dulbeccos’s modification of Eagle’s medium (DMEM). The mixtures were
incubated in HEPES buffer (25 mM, pH 7.4) for 20 minutes at room temperature and
subject to electrophoresis (100V, 1 h) in an agarose gel (1%) stained with ethidium
bromide (0.5 µg/ml).
4.4.6

Cell Culture
Two cell lines, HN12 96 and 293T, were used in this work. They were maintained

at 37 ˚C in a humidified atmosphere containing 10% CO2 and 90% air in growth medium
composed

of

DMEM

supplemented

with

penicillin-streptomycin (100 units/ml).
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fetal

bovine

serum

(10%)

and

4.4.7

Cytotoxicity Assay
To determine the cytotoxicity of G4.0-BAH-PEG conjugates, the HN12 cells

were seeded at a density of 5×103 cells/well in a 24-well cell culture plate at 37 ˚C. The
cells were allowed to grow for 24 hours. Afterwards, growth medium was replaced with 1
ml of fresh medium containing G4.0-BAH-PEG at different concentrations (0.2-100 µM).
G4.0 was used as a control. At 48 hours, cell viability was determined in triplicate using
the Trypan blue dye exclusion assay.
4.4.8

In vitro Transfection
293T cells and HN12 cells were seeded in 6-well plates at a density of 5×104

cells/well and allowed to grow in 2 ml of growth medium containing 10% FBS for 24
hours prior to transfection. The cells kept in the growth medium containing 10% FBS
were then transfected with the polyplexes of G4.0-BAH-PEG/GFP plasmid (100 µg/1 µg),
G4.0/GFP plasmid (100 µg/1 µg), PEI/GFP plasmid (20 µg/1 µg), and TransIT/GFP
plasmid (5 µl/1 µg), which were pre-dissolved in 100 µl of serum-free DMEM medium.
After 6-hour transfection treatment, the medium in each well was replaced with 2 ml of
fresh growth medium containing 10% FBS. The cells were further incubated for 48 hours
and then evaluated for transfection outcomes.
4.4.9

Western Blot
After the growth medium was removed, cells were washed twice with ice-cold

DPBS and lysed on ice for 10 minutes using 60 µl of cell lysis buffer (20mM HEPES, pH
7.5, 10mM EGTA, pH8.0, 40mM β-glycerophosphate, 1% NP-40, 2.5mM MgCl2,
20µg/ml aprotinin, 20µg/ml leupeptin, 1mM PMSF), scraped immediately, and
70

transferred to sterile 1.5 mL microcentrifuge tubes. Supernatant was transferred to a fresh
microcentrifuge tube after 10 min of microcentrifugation at 10,000 g at 4 °C. Cleared
lysates were quantified using a modified Bradford assay (BCA; Biorad, Hercules, CA),
and equivalent amounts of protein were resolved by SDS-PAGE and then transferred to
polyvinylidene difluoride (PVDF) membrane (Immobilon-P; Millipore, Billerica, MA).
Membranes were blocked in 5% skimmed milk in TTBS (10 mM Tris-HCl, pH 7.6, 0.5%
Tween-20, 150 mM NaCl) for 1 h at room temperature, and then incubated in primary
antibodies diluted 1:1000 in blocking buffer overnight at 4 °C. After washing in TTBS,
bound primary antibodies were detected using horseradish peroxidase conjugated
secondary antibodies and Western Lightning Enhanced Chemiluminescence (ECL;
Perkin-Elmer, Waltham, MA).
4.4.10

Fluorescence Microscopy
True-color fluorescent images of the cells transfected with pMAX-GFP plasmid

were taken using a Zeiss Axiovert 200 inverted fluorescence microscope (Carl Zeiss
Microimaging, Thornwood, NY).
4.4.11

Flow Cytometry
Following the removal of the growth medium, transfected cells were washed

twice with ice-cold DPBS and re-suspended using trypsin for 5-10 min. The cells were
fixed with cold 70% ethanol for 1 hour at 4 ºC, then centrifuged and washed with DPBS,
and transferred to microcentrifuge tubes containing 500 µl of PBS. Afterwards, the cells
were incubated with 1µg/ml RNase for 1 h at room temperature and stained with
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propidium iodide (50 µg/mL). The cells were then analyzed by using a Guava EasyCyte
mini flow cytometry system (Millipore, Billerica, MA).
4.4.12

Intracellular Trafficking Studies
G4.0 and G4.0-BAH-PEG42 were labeled with fluorescein isothiocyanate (FITC)

following our previous work 94. 293T cells were seeded on borosilicate glass cover slips
in 6-well plates at a density of 5×104 cells/well and allowed to grow in 2 ml of growth
medium containing 10% FBS for 24 hours. The cells were incubated with the polyplexes
of FITC-G4.0-BAH-PEG42 or FITC-G4.0 (control)/Label IT® Cy3™ plasmid (50 µg/0.5
µg in 100 µl of serum-free DMEM medium) for various lengths of time (i.e., 1h, 3h, and
6h), fixed with ice-cold methanol for 10 minutes, counterstained with DAPI, and then
rinsed with PBS buffer. Additionally, 293T cells incubated with the polyplexes for 6 h
were rinsed with PBS and then continuously cultured until 24 h or 48 h in 2 ml of fresh
growth medium containing 10% FBS. They were then fixed with ice-cold methanol for
minutes, counterstained with DAPI, and rinsed with PBS buffer. True-color fluorescent
images of the transfected cells were taken under a Zeiss Axiovert 200 inverted
fluorescence microscope (Carl Zeiss Microimaging, Inc., Thornwood, NY).
4.4.13

Statistical Analysis
All statistical analysis was based on a Kruskal–Wallis one way ANOVA on ranks

and a Tukey–Kramer pairwise multiple comparison procedure (α = 0.05) performed with
the JMP®Pro 10.0.0 statistical software package (SAS Institute, Inc.). Graphical
depictions of mean data were constructed with Microsoft Excel 2000, with error bars
representing standard deviations.
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4.5

Results and Discussion

4.5.1

Synthesis of G4.0-BAH-PEG Conjugates
G4.0-BAH-PEG conjugates were synthesized as illustrated in Scheme 1. EDA

core PAMAM dendrimer G4.0 containing 64 primary amine surface groups was chosen
as the underlying core. Its structure and purity have been reported previously

134,135

.

SANH is a hetero-bifunctional agent containing an amine-reactive NHS moiety and an
aldehyde-reactive hydrazine moiety. SANH was used to modify the amine-terminated
surface of G4.0 through its NHS moiety, hence introducing hydrazine moieties to the
dendrimer surface. Meanwhile, the amine group of monofunctional NH2-PEG-OCH3
(5000 gmol-1) was converted to a benzaldehyde moiety. The monofunctional
NH2-PEG-OCH3 was used here to avoid cross-reactions or loops that may form on the
dendrimer surface. SFB-activated PEG was then coupled to SANH-modified G4.0
through the formation of a stable bis-aryl hydrazone linkage. The final product was
dialyzed against deionized water for purification. The

1

H-NMR spectrum of

G4.0-BAH-PEG42 is shown in Fig. 4.2.

Figure 4.2

1

H-NMR spectrum of G4.0-BAH-PEG42 (MW of PEG is 5000 gmol-1).
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The spectrum confirms the presence of the methylene proton peaks of PEG (3.65
ppm, broad) and G4.0 (multiple methylene proton peaks between 2.4 ppm and 3.4 ppm).
Methyl end group (i) of PEG appears at 1.3 ppm. In addition, multiple proton peaks of
the BAH linkage appear between 7.2-10 ppm. According to the integration of the
corresponding proton peaks of PEG and G4.0, G4.0 dendritic macromolecules tethered
with an average of 3 or 42 PEG chains via bis-aryl hydrazone linkages were obtained and
used for further studies. In addition, 1H-NMR spectroscopy was applied to characterize
the products in acidic hydrolysis study. The degree of PEGylation remained unchanged
even after 24 hour-incubation at pH 4.0, suggesting that the synthesized conjugates were
resistant to acidic degradation.
4.5.2

Buffering Capacity of G4.0-BAH-PEG
Efficient gene transfer mediated by PAMAM dendrimers is in part due to their

high buffering capacity, which is responsible for the timely release of polyplexes from
the endosome and the lysosome. High buffering capacity of PAMAM dendrimers is
attributed to a large number of primary amine groups on the dendrimer surface and
tertiary amine groups inside the core. An acid-base titration assay was performed to
profile the buffering capacity of G4.0 and the synthesized PEGylated G4.0 with BAH
linkages. In general, the higher the buffering capacity of a synthetic vector, the greater
the resistance of its solution to pH change. In this work, the acid-base titration assay was
performed to profile the buffering capacity of the dendritic vector solutions containing
the same mass of vectors, which mirrored the preparation and use of the polyplexes in the
gene transfection studies in this work. As shown in Fig. 4.3., to decrease the pH value of
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the dendrimer solution (2.5 mg/5 ml) from 9 to 3, G4.0, G4.0-BAH-PEG3, and
G4.0-BAH-PEG42 solutions need 89 µL, 144 µL, and 178 µL of 0.1 M HCl, respectively.

Figure 4.3

Acid-base titration assay.

Solutions (5 mL) containing 2.5 mg of vector were adjusted to pH 9 with 0.1 M NaOH
and then titrated with 0.1 M HCl.
This result suggests that they have sufficient resistance to pH change and are
likely to be capable of facilitating the endosomal escape of polyplexes. In general, gene
vectors should have sufficient buffering capacity over a pH range of 5.5-6.0 in order to
permit polyplexes to escape from the endosome. The buffering capacity of G4.0-BAHPEG conjugates over a pH range of 5.5-6.0 was calculated on the basis of molarity and
compared to that of G4.0. The numerical calculation revealed that the buffering capacity
of G4.0-BAH-PEG3 was increased by 17% and that of G4.0-BAH-PEG42 was increased
by 377%. The increase in the buffering capacity of G4.0-BAH-PEG was attributed to the
incorporation of bis-aryl linkages into the conjugates. As demonstrated, a higher
percentage of PEGylation on the dendrimer surface with an enhanced buffering capacity
was enabled with the incorporation of bis-aryl hydrazone linkages.
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4.5.3

Analysis of Polyplex Formation
A gel retardation assay was performed to characterize the biophysical properties

of G4.0-BAH-PEG vectors in terms of the stability of polyplex formation.
G4.0-BAH-PEG conjugates were complexed with pMAX-GFP plasmid at various weight
ratios (0-40). According to the gel retardation assay (Fig. 4.4), at a weight ratio of 10 or
higher, the polyplexes of G4.0-BAH-PEG3/plasmid remain immobile, indicating that 10
is a minimal weight ratio for tightly condensing plasmid by G4.0-BAH-PEG3. The DNA
plasmid showed complete retardation at a weight ratio of 20 or higher with
G4.0-BAH-PEG42 (Figure 4.4). This study illustrates minimal weight ratios required for
G4.0-BAH-PEG vectors to neutralize the negatively charged GFP plasmid and form
stable polyplexes. Since the efficient adsorptive uptake of polyplexes by cells would be
enabled by the net positive charge of vector/plasmid polyplexes, a high weight ratio of
vector to plasmid (i.e., 100) was employed in gene transfection studies.

Figure 4.4

Gel retardation assay

(A) G4.0-BAH-PEG3/GFP plasmid complexes at weight ratios of 1, 2, 5, and 10 (left
to right). (B) G4.0- BAH-PEG42/GFP plasmid complexes at weight ratios of 0, 1, 2, 5,
10, 20, and 40 (left to right).
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4.5.4

Cytotoxicity
As shown in Fig. 4.5., at 0.2 µM, none of G4.0, G4.0-BAH-PEG3, and

G4.0-BAH-PEG42 induced an obvious cytotoxic response in HN12 tumor cells over a
period of 48 hours. Over the same period of time, G4.0 showed significant cytotoxic
response compared to G4.0-BAH-PEG3 and G4.0-BAH-PEG42 at 2 µM. At 20 µM,
G4.0-BAH-PEG42

displayed

significant

cytocompatibility

than

G4.0

and

G4.0-BAH-PEG3. Given that G4.0-BAH-PEG3 did not show improved cytocompatibility,
G4.0-BAH-PEG42 was evaluated further in gene transfection studies.

Figure 4.5 Dose-dependent cytotoxic effect of G4.0 (control) and G4-BAH-PEG
conjugates on the viability of HN12 cells.
HN12 cells were seeded in culture plates, exposed to the indicated concentrations of
dendrimer conjugates, and cell viability at 48 h determined by the Trypan blue assay. #
indicates significant differences from G4.0 group compared with other groups at 2
µM. * indicates significant differences from G4.0-BAH-PEG42 group compared with
other groups at 20 µM.
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4.5.5

In vitro Transfection Studies
The in vitro gene transfection efficiency of G4.0-BAH-PEG42 was evaluated

using 293T and HN12 cell lines with GFP plasmids as reporters. PEI (25 kDa) is an
efficient gene transfection agent and commonly used as a “gold standard” although it has
appreciable toxicity. TransIT-keratinocyte transfection reagent (simply referred to as
TransIT) is a commercially available transfection reagent with high efficiency and low
toxicity. Both PEI and TransIT were used as controls in this work. To ascertain whether
the use of the BAH linkage would result in improved gene transfection, G4.0-mediated
gene transfection was evaluated for direct comparison. Although increasing vector to
plasmid ratios very likely augments the gene transfection efficiency, cytotoxicity of the
vector at high concentrations should also be balanced, particularly for PEI, which has
high toxicity. Therefore, gene transfection of the vectors should be evaluated in
conjunction with their potential toxic effects on transfected cells. PEI was complexed
with GFP plasmid at a weight ratio of 20:1, which was shown to generate appreciably
high gene transfection efficiency under the condition used in this work. The transfection
efficiency was evaluated using GFP expression, which was qualitatively illustrated by
fluorescence microscopy and quantified by both flow cytometry and western blot. The
cell viability after transfection was assessed as well.
The fluorescence images of GFP-expressing 293T cells are shown in Fig. 4.6. It is
apparent that PEI-mediated gene transfer has resulted in the highest percentage of
transfected 293T cells with the strongest fluorescence (Fig. 4.6.B.). The cellular
morphology of the transfected cells remained unchanged, indicating the minimal toxic
effect of PEI. TransIT-mediated gene transfer resulted in a moderate percentage of
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transfected 293T cells (Fig. 4.6.C.), which is similar to the outcome of gene transfection
by G4.0-BAH-PEG42 (Fig. 4.6.E.). As shown in Fig. 4.6.D., 293T cells are sparsely
transfected when using G4.0.

Figure 4.6 Fluorescence images of 293T cells (untreated, A) and transfected with
GFP plasmid mediated with PEI (B), TransIT (C), G4.0 (D), and G4-BAH-PEG42
(E). (x100)
The cells were exposed to the vector/GFP plasmid polyplexes for 6 h, rinsed, and then
cultured for another 48 h.
In addition, the 293T cells suffered from the toxicity of G4.0, which was
confirmed by the cell viability assessment done after gene transfection studies (Fig. 4.7.).
In contrast, the viability of the 293T cells treated with G4.0-BAH-PEG42 remained
unchanged.
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Figure 4.7 Cell viability of 293T and HN12 post-transfection as determined by the
Trypan blue assay.
The cells were exposed to the vector/GFP plasmid polyplexes for 6 h, rinsed, and then
cultured for another 48 h. # and * indicates significant differences from G4.0 group
compared with other groups in HN12 Cells and 293T cells separately. ## and **
indicates significant differences from PEI group compared with other groups in HN12
Cells and 293T cells separately.
Flow cytometry analysis revealed that the proportion of 293T cells transfected
was 28.0% by PEI, 5.1% by TransIT, 1.1% by G4.0, and 3.5% by G4.0-BAH-PEG42 (Fig.
4.8.A). The transfection efficiency of G4.0-BAH-PEG42 was three times that of
unmodified G4.0 in terms of the percentage of transfected cells. Western blotting was
used to quantify the levels of GFP expression in the transfected cells (Fig. 4.9.). Again,
the western blot results confirmed that G4.0 has the lowest transfection efficiency in
terms of the ability to induce transgene expression in 293T cells (Fig. 4.9.A).
G4.0-BAH-PEG42-mediated gene transfer has resulted in an increase of 53% in the
overall amount of GFP expressed in the 293T cells as compared to G4.0-medidated gene
transfer. The gene transfection studies based on 293T cells showed that G4.0-BAHPEG42 is able to transfect significantly more 293T cells and induce a higher level of GFP
expression than unmodified G4.0.

80

Figure 4.8 Efficiency of transfection agents in 293T (A) and HN12 (B) as
determined by flow cytometry.
The cells in 2 mL of growth medium containing 10% FBS were exposed to the
polyplexes (PEI/plasmid: 20 µg/1 µg; TransIT/plasmid: 5 µL/1 µg; G4.0/plasmid: 100
µg/1 µg; G4-BAH-PEG42/plasmid: 100 µg/1 µg) for 6 h, rinsed, and then cultured for
another 48 h prior to flow cytometry analysis. Untreated cells were used as negative
control. # indicates significant differences from PEI group compared with other
groups. * indicates significant differences from G4.0-BAH-PEG42 group compared
with other groups.
HN12 cells are difficult to transfect, and only a small proportion of HN12 cells
were transfected regardless of transfection agents. According to the flow cytometry
results, the percentage of HN12 cells transfected was 5.1% by PEI, 3.4% by TransIT,
2.3% by G4.0, and 3.3% by G4.0-BAH-PEG42 (Fig. 4.8.B.). The GFP expression in
HN12 cells transfected by G4.0-BAH-PEG42 was 80% more than those transfected by
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G4.0 (Fig. 4.9.B.). The western blot results indicate that the ability of G4.0-BAH-PEG42
was similar to that of TransIT in inducing GFP expression in HN12 cells.

Figure 4.9
(B).

Western blot analysis of GFP expression in 293T (A) and HN12 cells
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The cells in 2 mL of growth medium containing 10% FBS were exposed to the
polyplexes (PEI/plasmid: 20 µg/1 µg; TransIT/plasmid: 5 µL/1 µg; G4.0/plasmid: 100
µg/1 µg; G4-BAH-PEG42/plasmid: 100 µg/1 µg) for 6 h, rinsed, and then cultured for
another 48 h prior to flow cytometry analysis. Untreated cells were used as negative
control. # indicates significant differences from PEI group compared with other
groups. * indicates significant differences from G4.0-BAH- PEG42 group compared
with other groups.
Although the transfection efficiency of a vector significantly depends on the
target cell type, G4.0-BAH-PEG42 showed higher transfection efficiency than G4.0 in
both cell lines tested in the present study while exerting considerably less toxic effects on
transfected cells, suggesting that the incorporation of bis-aryl hydrazone linkages into the
PEGylated dendrimer vector indeed resulted in enhanced gene transfection. To
understand the intracellular trafficking pattern of the internalized dendrimer/plasmid
polyplexes in living cells, colocalization assays were performed to assess the distribution
of the polyplexes in 293T cells at various time points post-transfection. The dendritic
vectors (i.e., G4.0 and G4.0-BAH-PEG42) were labeled with FITC. A cyanine dye
-labeled plasmid (i.e., Label IT® Cy3™ plasmid) was employed for in vitro tracking of
plasmid. Time lapse imaging and colocalization results qualitatively show the
internalization of G4.0-BAH-PEG42/plasmid polyplexes was stronger than that of
G4.0/plasmid polyplexes within the first hour (Fig. 4.10.).
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Figure 4.10 Intracellular trafficking of FITC-labeled dendrimer (green)/Label
IT® Cy3™ plasmid (red) polyplexes in 293T cells with cell nuclei counterstained
with DAPI at 1 h post-transfection (x630)
As time progressed, more polyplexes of G4.0/plasmid were internalized. However,
the dissociation of G4.0/plasmid polyplexes became noticeable at 3h and 6h (Fig. 4.11.).
In contrast, G4.0-BAH-PEG42/plasmid polyplexes were still tightly complexed and found
in the nuclei of 293T cells. The accumulation of G4.0-BAH-PEG42/plasmid polyplexes in
the nuclei at 24 h (Fig. 4.11.) and 48 h (not shown) became more evident as opposed to
G4.0/plasmid polyplexes, which could be attributed to enhanced gene transfection.
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Figure 4.11 Colocalization of FITC-labeled dendrimer (green)/Label IT® Cy3™
plasmid (red) polyplexes in 293T cells with cell nuclei were counterstained with
DAPI at various time points. (x630)
4.6

Conclusions
PEGylated PAMAM dendrimer G4.0 conjugates with bis-aryl hydrazone linkages

(i.e., G4.0-BAH-PEG) were successfully synthesized and evaluated as a new vector. The
incorporation of bis-aryl hydrazone linkages into the vector significantly enhanced the
buffering capacity of the vector even with a high degree of PEGylation (42 PEG chains
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per dendrimer). G4.0-BAH-PEG conjugates could complex tightly with plasmid DNA at
low weight ratios and displayed dramatically improved cytocompatibility. According to
the gene transfection studies based on 293T and HN12 cells, this new vector has been
shown to be capable of both transfecting more cells and inducing higher GFP expression
than unmodified G4.0. This work has demonstrated that the use of bis-aryl hydrazone
linkage in coupling of PEG to the dendrimer helps maintain or increase the buffering
capacity of the functionalized dendrimer and results in enhanced gene transfection.
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5.1

Hypothesis and Specific Aims
Dendrimers have appeared as promising vehicles for efficient delivery of a wide

spectrum of CNS therapeutics to the brain. Buccal mucosa is always used as an
absorption site for administration of CNS therapeutic nanoparticles. Gelatin/PEG sIPN
hyrogel displays good biodegradability, moderate stiffness, and satisfactory tissue
adhesiveness. Furthermore, gelatin/PEG sIPN can deliver and release biomacromolecules
in a controlled way. We hypothesize that hydrogel platform will enhance the
permeability of dendritic nanoparticles through buccal mucosa membrane.
To test the above hypotheses, we propose three specific aims in this section as
follows:
Specific Aim 1: Design, synthesize and characterize a novel brain-targeted dendrimerbased nanoparticulate drug delivery system;
Specific Aim 2: Evaluate the permeability across the buccal membrane;
Specific Aim 3: Construct a hydrogel platform for buccal adhesion and evaluate its
permeability.
5.2

Abstract
This work utilized polyamidoamine (PAMAM) dendrimer G4.5 as the underlying

carrier to construct CNS therapeutic nanoparticles and explored the buccal mucosa as an
alternative absorption site for administration of the dendritic nanoparticles. Opioid
peptide DPDPE was chosen as a model CNS drug. It was coupled to PAMAM dendrimer
G4.5 with polyethylene glycol (PEG) or with PEG and transferrin receptor monoclonal
antibody OX26 (i.e., PEG-G4.5-DPDPE and OX26-PEG-G4.5-DPDPE). The therapeutic
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dendritic nanoparticles labeled with 5-(aminoacetamido) fluorescein (AAF) were studied
for transbuccal transport using a vertical Franz diffusion cell system mounted with
porcine buccal mucosa. For comparison, AAF-labeled PAMAM dendrimers G3.5 and
G4.5, and fluorescein isothiocyanate (FITC)-labeled G3.0 and G4.0 were also tested for
transbuccal delivery. The permeability of PEG-G4.5 (AAF)-DPDPE and OX26-PEGG4.5(AAF)-DPDPE were on the order of 10-7 - 10-6 cm/s. Coadministration of bile salt
sodium

glycodeoxycholate

(NaGDC)

enhanced

the

permeability

of

dendritic

nanoparticles by multiple folds. Similarly, a multifold increase of permeability of
dendritic nanoparticles across the porcine buccal mucosal resulted from the application of
mucoadhesive gelatin/PEG semi-interpenetrating network (sIPN). These results indicate
that transbuccal delivery is a possible route for administration of CNS therapeutic
nanoparticles.
5.3

Introduction
Nanoparticles have appeared as promising vehicles for efficient delivery of a wide

spectrum of CNS therapeutics (e.g., nucleic acids, proteins, or short peptides) to the brain
37,136-138

. Due of the susceptible structures of those bioactive molecules, therapeutic

nanoparticle are often administered systemically, most likely via intravenous (i.v.)
injection to avoid the first pass effect and enhance their bioavailability

139

. Nonetheless,

i.v. injection causes poor patient compliance. With the significant increase in the number
of CNS drug prescriptions worldwide as predicted, the societal burden of health care
services and the risk of cross-contamination of i.v. injection, particularly in developing
countries, will be high. Thus, exploring non-invasive and safe administration routes for
CNS therapeutic nanoparticles is highly demanded.
89

Our goal was to develop a modality to administer CNS therapeutic nanoparticles
non-invasively. The objective of this work was to apply dendrimers as carriers to deliver
CNS drugs and explore the buccal mucosa as an absorption site for administration of
CNS therapeutic nanoparticles. The buccal membrane in the oral cavity has a large area,
is less affected by saliva, and holds the dosage form for a relative long time, thus
allowing drug molecules to enter the systemic circulation by avoiding first-pass effect.
Buccal administration requires much less health care service and offers the advantage of
being relatively painless, which are particular benefits for patients suffering from chronic
CNS disorders. Dendrimers are a class of suitable carriers for construction of
nanodevices and nanomedicines

140,141

. They possess a highly branched, nanoscale

architecture with very low polydispersity and high functionality 140,142,143. The presence of
numerous surface groups allows a high drug payload and/or multifunctionality on the
dendrimer surface. Several studies have shown that therapeutic molecules can cross cell
membranes or biological barriers with the aid of dendrimers.
In the present study, DPDPE was chosen as a model drug because it is a
well-characterized opioid peptide and has been widely applied to reveal new mechanisms
to enhance delivery of peptides into the CNS. Polyamidoamine (PAMAM) dendrimer
G4.5 was chosen as the underlying carrier. DPDPE was coupled to the surface of
PAMAM dendrimer G4.5 along with polyethylene glycol (PEG). PEG was incorporated
into this delivery system to overcome reticuloendothelial system (RES) uptake, reduce
immunogenicity and cytotoxicity, and generate favorable pharmacokinetic (e.g.,
half-lives) and tissue distribution. Additionally, conjugated PEG chains were used as
anchoring sites for coupling of such targeting ligand molecules as OX26, for targeted
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drug delivery. Porcine buccal mucosa was used as a model to evaluate the permeability of
the constructed delivery system as it is analogous to normal human buccal epithelium in
terms of thickness, morphology, structure, and composition

144,145

. The transbuccal

transport of fluorescently labeled PAMAM dendrimers (G3.0, G3.5, G4.0, and G4.5) was
investigated for comparison. Bile salt sodium glycodeoxycholate was studied for
enhanced transbuccal transport of the therapeutic dendritic nanoparticles. In addition,
mucoadhesive semi- interpenetrating network (sIPN) of gelatin/PEG was applied to
formulate buccal adhesive patches for encapsulation and release of the dendritic
nanoparticles. The permeability of encapsulated dendritic nanoparticles was studied.
5.4
5.4.1

Materials and Methods
Materials
Ethylene diamine-core polyamidoamine (PAMAM) dendrimers G3.5 and G4.5

with carboxylate end groups and G3.0 and G4.0 with amine end groups were purchased
from

Dendritech

(Midland,

MI).

Benzylamine,

N-hydroxysuccinimide

(NHS),

1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), fluorescein
isothiocyanate (FITC), FITC-dextran (FD-4, average molecular weight 3000-5000 Da),
and sodium glycodeoxycholate (NaGDC) were obtained from Sigma-Aldrich (St. Louis,
MO). 5-(Aminoacetamido) fluorescein (AAF) was purchased from Invitrogen (Carlsbad,
CA). [D-Pen 2, 5]-Enkephalin (DPDPE) was purchased from AnaSpec (Fremont, CA).
Hetero-bifunctional amine-PEG-maleimide (MW=3400 Da) was purchased from
Creative PEGWorks (Winston Salem, NC). Dialysis membrane (MWCO 14 kDa) was
purchased from Spectrum® Laboratories (Rancho Dominguez, CA). Mouse monoclonal
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transferrin receptor antibody OX26 (simply referred to as OX26) was purchased from
Abcam (Cambridge, MA). Traut’s reagent (i.e., 2-iminothiolane) was purchased from
Thermo Scientific (Rockford, IL). Polyvinylidene difluoride (PVDF) membranes
(Immobilon-P) were purchased from Millipore (Billerica, MA). Peroxidase conjugated
anti-human secondary antibody was purchased from MP Biomedical (Aurora, OH). All
other reagents and solvents used in this work were of analytical grade.
5.4.2

Preparation of PEG-G4.5-DPDPE Conjugates
To synthesize DPDPE-carrying dendrimer conjugates, 13.1 mg PAMAM G4.5

(0.5 µmol), obtained upon removal of methanol from the storage solution via rotary
evaporation, was dissolved in 2 mL of deionized water and acidified to pH 1.0 with 1 N
hydrochloric acid. The acidified G4.5 was evaporated to dryness and then re-dissolved in
2 mL of a mixture dimethylformamide (DMF)/water solution (80/20 v/v). To the G4.5
solution 8.9 mg of NHS (77 µmol) and 15.9 mg of EDC (77 µmol) were added. After a
14-h reaction while stirring, the resulting NHS-activated G4.5 was dried and re-dissolved
in pH 8.5 sodium bicarbonate solution. PEG-α-amine-ω-maleimide (3.1 mg, 0.9 µmol)
pre-dissolved in pH 8.5 sodium bicarbonate solution was added to the G4.5-NHS solution
to initiate a coupling reaction for 3-4 h. Afterwards, 150 µg of AAF (0.36 µmol) in
sodium bicarbonate solution was added slowly to the above reaction mixture and stirred
for 2 h. Finally, 1.9 mg DPDPE (2.9 µmol) was added to the reaction solution for another
3-4 h reaction. The resulting PEG-G4.5-DPDPE conjugates were subjected to dialysis
using a dialysis tube with MWCO 14 kDa and then freeze-dried using a Flexi-Dry MP™
Freeze-Dryer (FTS, Stone Ridge, NY). Degree of PEGylation and DPDPE loading
density were estimated using 1H-NMR spectroscopy.
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5.4.3

Preparation of OX26-PEG-G4.5-DPDPE Conjugates
OX26 was coupled to the dendrimer surface via PEG spacer. Briefly, OX26

dissolved in 0.15 M sodium borate buffer/0.1 mM EDTA (pH 8.5) was reacted with
Traut’s reagent for 1 h at room temperature, where a feed molar ratio of 40:1 for
2-iminothiolane/OX26 was used 146,147. PEG-G4.5-DPDPE conjugates were then added to
the solution to react with thiolated OX26 overnight with gentle shaking, in which the
molar ratio of thiolated OX26 to maleimide was kept at 1:3

147

. The resulting

OX26-PEG-G4.5-DPDPE conjugates were dialyzed for purification.
5.4.4

Fluorescein Labeling of PAMAM Dendrimers
AAF-labeled half-generation PAMAM dendrimers were prepared using

NHS/EDC coupling chemistry, similar to coupling of DPDPE to PAMAM dendrimer
G4.5. FITC-labeled full generation PAMAM dendrimers G3.0 and G4.0 were prepared
following our previous work 148.
1

5.4.5
1

H-NMR spectroscopy

H-NMR spectra were obtained on a Varian superconducting Fourier-transform

NMR spectrometer (Mercury-300). Deuterium oxide (D2O, 99.9%) was used as the
solvent, which has a chemical shift of 4.8 ppm for D2O residue.
5.4.6

Size and Zeta Potential Measurements
Size and zeta potential of PAMAM dendrimer derivatives in pH 7.4 PBS were

measured at room temperature using Malvern Zetasizer Nano S (Malvern Instruments,
Worcestershire, UK).
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5.4.7

Fluorometry
Fluorescence spectra were collected on a Cary Eclipse fluorescence

spectrophotometer (Varian, Palo Alto, CA) for characterization and quantification of
fluorescently-labeled dendrimers. FITC-labeled dendrimers and FD-4 were measured at
the excitation wavelength of 490 nm and the emission wavelength of 520 nm.
AAF-labeled dendrimers were measured at the excitation wavelength of 488 nm and the
emission wavelength of 515 nm.
5.4.8

UV-Vis Spectrophotometry
In permeation studies, UV-Vis spectrophotometry was applied to quantify

benzylamine at the wavelength of 254 nm using a GENESYS™ 6 UV-Vis
spectrophotometer.
5.4.9

Western Blotting
OX26-PEG-G4.5-DPDPE was assessed by western blotting, whereas free OX26

was included as control. They were resolved by SDS-PAGE and then transferred to a
polyvinylidene difluoride (PVDF) membrane (Immobilon-P). The membrane was
blocked in 5% skimmed milk in TTBS (10 mM Tris-HCl, pH 7.6, 0.5% Tween-20, 150
mM NaCl) for 1 h at room temperature and then incubated in peroxidase conjugated
anti-human secondary antibody diluted 1:1000 in blocking buffer overnight at 4 °C. After
washing in TTBS, the antibodies were detected using Western Lightning Enhanced
Chemiluminescence (ECL; Perkin-Elmer, Waltham, MA).
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5.4.10

Cytotoxicity Studies
Human dermal fibroblasts were seeded at a density of 2×104 cells/well in a 6-well

cell culture plate. They were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U ml-1 penicillin, and
100 µg ml-1 streptomycin at 37 °C in a humidified atmosphere containing 5% CO2 in air.
The seeded cells were allowed to grow for 24 h and then treated with dendrimer
derivatives at various concentrations (0.02-2 mg/ml) for 6 h or 72 h. Cell viability was
then determined using the Trypan blue dye exclusion assay.
5.4.11

In vitro Permeation Studies
Porcine cheek tissues were obtained from freshly sacrificed pigs (Silver Ridge

Slaughter House, Fredericksburg, VA) and transferred to the lab within 2h. Mucosa
tissues were excised and cut into approximately 2 cm2 and frozen on aluminum foil at -20
°C until used. Before permeation studies, frozen specimens were equilibrated in pH 7.4
PBS for 1 h at room temperature to thaw completely. Excesses of connective and adipose
tissues were trimmed off with surgical scissors to a thickness of approximately 0.6 ± 0.1
mm as determined by using a digital caliper.
Buccal mucosa membrane was mounted on a vertical Franz diffusion cell
(PermeGear, Hellertown, PA) with the epithelium facing the donor chamber and the
connective tissue facing the receiver chamber. The Franz diffusion cell had a diffusion
area of 0.785 cm2 with a donor chamber volume of 1 mL and a receiver chamber volume
of 5 mL. The cell was placed in an incubator, in which temperature was maintained at 37
°C and protected against light.
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Permeation experiments were carried out using pH 7.4 PBS in the receiver
chamber and pH 6.8 PBS in the donor chamber to mimic the in vivo physiological
conditions. After an equilibration period of 30 min, PBS in the donor chamber was
replaced with 1 mL of PBS containing pre-dissolved dendrimers. In some experiments,
NaGDC was co-administered for enhanced transbuccal transport. Its concentration in the
donor chamber was kept at 10 mM. To study transbuccal transport of dendrimer
nanoparticles loaded into hydrogels, dendrimer-loaded gelatin/PEG sIPN and PEG-only
hydrogel disks were prepared as described previously

149

. The gel disks of the same size

of the permeation surface were placed on top of the mucosa membrane and immersed
with 1 mL of pH 6.8 PBS. At a given time point up to 5 h, an aliquot of 0.5 mL from the
receiver chamber was collected via syringe and analyzed with fluorometry. FD-4 and
benzylamine were included as negative and positive control, respectively.
Permeability coefficient, P, was calculated as follows:

where dQ/dt

is the steady-state slope of a cumulative flux curve, C is the loading concentration of a
permeant in the donor chamber, and A (0.785 cm2) is the effective cross-sectional area
available for diffusion. Flux (µg/cm2/h) is determined by

. Upon the completion

of the permeation experiments, the buccal mucosal tissues were processed to get frozen
and hematoxylin and eosin (H&E) stained tissue slices for microscopic examination.
5.4.12

Data Analysis
All statistical analysis was based on a Kruskal–Wallis one way ANOVA on ranks

and a Tukey–Kramer pairwise multiple comparison procedure (α = 0.05) performed with
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the JMP®Pro 10.0.0 statistical software package (SAS Institute, Inc.). Graphical
depictions of mean data were constructed with Microsoft Excel 2000, with error bars
representing standard deviations.
5.5
5.5.1

Results and Discussion
Characterization of Dendrimer Conjugates
In this work, we developed a CNS drug delivery system based on highly branched,

well defined PAMAM dendrimers. We chose G4.5 as the underlying carrier because it
has as many as 128 surface carboxylate groups, high cytocompatibility, and low
non-specific cellular uptake. Since various functional moieties including DPDPE, PEG,
fluorescent probe, and targeting ligand OX26 were to be incorporated into the delivery
system, we proposed a layer-by-layer assembly strategy to prevent potential
cross-reactions. As illustrated in Fig.5.1, only complementarily reactive functional groups
were made available for coupling reaction in each step: NH2 and NHS ester in step 1, and
maleimide and thiol in step 2.
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Figure 5.1 Synthesis of PEG-G4.5 (AAF)-DPDPE and OX26-PEG-G4.5 (AAF)DPDPE conjugates
Thiolated OX26 has proven to be efficient in coupling with maleimide-containing
polymer 146,147. As thiolation only happens on the carbohydrate part of the Fc portion, the
transferrin receptor-recognizing ability of OX26 is preserved 150.
Identification of the maleimide proton peak of PEG (δ 6.69 ppm, peak A), the
methylene proton peak of PEG (δ 3.69 ppm, peak B), the methylene proton peak of
DPDPE (δ 2.15 ppm, peak C), and multiple proton peaks of G4.5 between 2.19 and 3.47
ppm indicates the success of the synthesis of PEG-G4.5-DPDPE conjugates (Fig. 5.2.).
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Figure 5.2 Synthesis of PEG-G4.5 (AAF)-DPDPE and OX26-PEG-G4.5 (AAF)DPDPE conjugates
Following the methodology described in our previous work

127

, a further

calculation was conducted based on the integrals of the corresponding peaks in the
spectrum and determined that 97 DPDPE molecules and three PEG chains on average
were coupled to PAMAM dendrimer G4.5.
To track dendrimers for quantitative assessment of their transbuccal transport,
PAMAM dendrimers studied were labeled with fluoresceins. FITC was used to label
amine-terminated PAMAM dendrimers G3.0 and G4.0. AAF was used to label
carboxylate-terminated PAMAM dendrimers G3.5, G4.5, and functionalized PAMAM
dendrimer G4.5. PEG-G4.5 (AAF)-DPDPE displayed a measurable size of 73.65±5.96
nm, a nearly 16-fold increase as compared to G4.5-AAF (Fig 5.3.).
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Table 5.1 Size and zeta potential of the tested permeants in pH 7.4 PBS at room
temperature
Permeant
G3.0-FITC
G3.5-AAF
G4.0-FITC
G4.5-AAF
PEG-G4.5 (AAF)-DPDPE
OX26-PEG-G4.5(AAF)-DPDPE
FD-4

Size (nm)
3.61 ± 0.71
5.46 ±0.39
10.02 ± 0.85
5.54 ± 0.94
73.65 ± 5.96
166.20±10.11
77.32 ± 4.68

Zeta potential (mV)
10.20 ± 0.44
-10.54 ± 0.29
11.99 ± 2.64
-14.23 ± 0.72
-3.50 ± 0.12
-1.5±0.28
-4.27 ± 0.59

PDI
0.427
0.487
0.851
0.652
0.635
0.336
0.479

This dramatic size increase was attributed to the conjugation of PEG and DPDPE
to the dendrimer and, very likely, the flocculation of individual particles due to
entanglement of PEG chains. As a result of surface modification of G4.5, the zeta
potential changed from -14.23±0.72 mv for G4.5-AAF to -3.50±0.12 mv for PEG-G4.5
(AAF)-DPDPE. Success of coupling OX26 to PEG-G4.5 (AAF)-DPDPE was confirmed
by western blotting (Fig. 5.3.) as well as size increase and zeta potential reduction (Table.
5.1.).

Figure 5.3

Western blotting of OX26 and OX26-PEG-G4.5-DPDPE

Coupling fluoresceins and other types of moieties to the dendrimer surface
resulted in changes in particle size and surface properties. The size and zeta potential of
the prepared fluorescently-labeled dendrimer derivatives were summarize in Table. 5.1. It
is noteworthy that the values of size and zeta potential of dendrimer derivatives reported
herein only reflected the surface treatment specified in this work.
100

5.5.2

Cytotoxicity of Dendrimer Conjugates
The toxicity of PAMAM dendrimers studied in this work was found to be

dependent on multiple factors including concentration, generation, surface composition,
and incubation period (Fig. 5.4.).

Figure 5.4 Viability of human dermal fibroblasts incubated with PAMAM
dendrimer derivatives for 72 h (A) and 6 h (B)
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At 6h, all the materials induced significant cytotoxicity at 2 mg/ml compared to
20 µg/ml or 200 µg/ml. For a given dendrimer derivative, a shorter period of contact with
human dermal fibroblasts at some concentrations had much less toxic effects. For
example, the viability of the cells incubated with 200 µg or 2mg/ml G4.0-FITC increased
significantly when the incubation period was shortened from 72 h to 6 h. At 2mg/ml
G3.0-FITC, G3.5-AAF or G4.5-AAF, the cell viability increased significantly when the
incubation time was shortened from 72 h to 6 h. As for PEG-G4.5 (AAF)-DPDPE at 2
mg/ml, the cell viability also increased significantly following 72 h-incubation.
Regardless of the length of incubation period, PEG-G4.5 (AAF)-DPDPE at
concentrations up to 200 µg/ml showed good cytocompatibility.
5.5.3

In Vitro Permeation Studies
To study transport of PAMAM dendrimers across the porcine buccal mucosa, the

permeability of fluorescently labeled biofunctionalized PAMAM dendrimer G4.5
derivatives, cationic PAMAM dendrimers (G3.0 and G4.0), and anionic PAMAM
dendrimers (G3.5 and G4.5) was measured. FD-4 as negative control and benzylamine as
positive group were included. As seen from Fig. 5.5., all the cumulative flux curves
display a linear range, indicating a steady state transport of the tested permeants via the
paracellular route.
Permeability was then calculated from the linear range of the cumulative flux
curves. Buccal mucosa tissue integrity was confirmed by the low permeability of FD-4,
i.e., 9.59×10-7 cm/s. As expected, benzylamine penetrated the buccal mucosa at a
distinctly high influx rate. Its permeability was determined to be 1.01×10-5 cm/s.
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Figure 5.5 Transport of PAMAM dendrimer nanoparticles across the porcine
buccal mucosa
Hydrophilic molecules can cross the buccal membrane via the paracellular route,
which is driven by passive diffusion. G3.0-FITC and G4.0-FITC were found to have
significantly higher permeability than G3.5-AAF and G4.5-AAF (Table 5.2.).
Table 5.2

Permeability of the model permeants across the porcine buccal mucosa
Permeant

Permeability (cm/s)

G3.0-FITC
5.45×10-6
G3.5-AAF
2.65×10-7
G4.0-FITC
8.92×10-7
G4.5-AAF
1.06×10-7
PEG-G4.5 (AAF)-DPDPE
3.31×10-6
OX26-PEG-G4.5(AAF)-DPDPE
7.89×10-7
a
FD-4
9.59×10-7
Benzylamineb
1.01×10-5
a
Negative control; bpositive control.
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This result was consistent with a recent study showing that cationic PAMAM
dendrimers can gain enhanced transport by causing opening of epithelial tight junctions
and toxicity effects

151

. Interestingly noted was that the permeability of PEG-G4.5

(AAF)-DPDPE was one order of magnitude higher than G4.5-AAF although its size was
12-fold larger. Enhanced transport of PEG-G4.5 (AAF)-DPDPE was presumably
attributed to its reduced zeta potential, which, in turn, resulted in enhanced transport of
PEG-G4.5 (AAF)-DPDPE across the buccal mucosa tissue. The permeability of
OX26-PEG-G4.5(AAF)-DPDPE was lower than that of PEG-G4.5(AAF)-DPDPE by
approximately 74%. Nonetheless, the permeability of PEG-G4.5 (AAF)-DPDPE and
OX26-PEG-G4.5(AAF)-DPDPE were on the order of 10-7 - 10-6 cm/s (Table. 5.2), which
was higher than that of G4.5-AAF.
The presence of OX26-PEG-G4.5(AAF)-DPDPE permeated through the buccal
mucosa was further confirmed by western blotting (Fig. 5.6.).

Figure 5.6 Western blot of OX26-PEG-G4.5 (AAF)-DPDPE permeated through
the porcine buccal mucosa at the indicated time points
According to the microscopic examination of the buccal tissues used in the
transport studies of G4.5-AAF and PEG-G4.5 (AAF)-DPDPE, the treated samples did not
show any significant difference compared to the untreated tissue (Fig. 5.7.A). The
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fluorescence images (Fig. 5.7.B) indicate the presence of G4.5-AAF and PEG-G4.5
(AAF)-DPDPE in the buccal tissues.

Figure 5.7 Microscopic examination of the porcine buccal tissues. Panel A: H&E,
panel B: fluorescence imaging
It was reported that anionic PAMAM dendrimers showed rapid serosal transfer
rates in crossing adult rat intestine in vitro and had low tissue deposition
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. The

transport of PAMAM and surface-modified PAMAM across cell monolayer may follow
endocytosis-mediated cellular internalization

153

. Therefore, a mechanistic understanding

of transport of dendritic nanoparticles across the buccal mucosa is needed and will be
explored in future work.
Flux of nanoparticles across the buccal mucosal membrane can be increased by
either elevating nanoparticle concentration gradient for greater fickian diffusion or
increasing the permeability of nanoparticles 154. The latter approach is preferred as it does
105

not require a high load of therapeutic nanoparticles at the absorption site. Bile salts as
penetration enhancer have been applied to enhance permeability of compounds of interest
in transbuccal permeation

145

. Our work showed that coadministration of NaGDC at 10

mM enhanced the transbuccal permeation of dendrimer nanoparticles (Fig. 5.8.A).
The permeability enhancement ratios of FD-4, G4.5-AAF and PEG-G4.5
(AAF)-DPDPE were 4.5, 47.5 and 2.3 by using NaGDC, respectively. The permeability
enhancement ratios of FD-4, G4.5-AAF and PEG-G4.5 (AAF)-DPDPE were 0.4, 4.0 and
3.2 by using PEG-only hydrogel, respectively. The permeability enhancement ratios of
FD-4, G4.5-AAF and PEG-G4.5 (AAF)-DPDPE were 0.3, 4.0 and 2.7 by using
Gelatin/PEG sIPN hydrogel, respectively.
This enhanced transbuccal transport is presumably attributed to the altered intraand extra-cellular distribution of permeants by bile salts
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. Therefore, the low

permeability enhancement ratio of PEG-G4.5 (AAF)-DPDPE by NaGDC indicates that
the intra- and extra-cellular distribution of PEG-G4.5 (AAF)-DPDPE might be close to
an optimal distribution both intra- and extra-cellularly. An in-depth examination is
needed to gain a clear mechanistic understanding of how structure and composition affect
the transport of dendritic nanoparticles across the buccal mucosa. Nonetheless, the use of
bile salts is essential for enhanced transbuccal delivery of dendrimers.
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Figure 5.8 Transport of PAMAM dendrimer nanoparticles across the porcine
buccal mucosa with coadministration of sodium glycodeoxycholate (A), from
gelatin/PEG sIPN (B), and from PEG-only gel (C).
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Gelatin/PEG sIPN displays good biodegradability, moderate stiffness, and
satisfactory tissue adhesiveness

155,156

. Furthermore, gelatin/PEG sIPN can deliver

biomacromolecules such as basic fibroblast growth factor and release it in a controlled
manner 157. Therefore, this mucoadhesive sIPN platform was adopted to formulate buccal
patches for delivery of functionalized PAMAM dendrimers. A hydrogel made of PEG
only (i.e., PEG-only hydrogel) was used as control. Encapsulated dendrimer
nanoparticles were able to permeate through the buccal mucosa at detectable rates as
shown in Fig. 5.8. Impressively, permeability of G4.5-AAF and PEG-G4.5(AAF)DPDPE was increased significantly after being loaded into sIPN. A 300% increase in
permeability for G4.5-AAF and a 170% increase for PEG-G4.5 (AAF)-DPDPE were
observed. One of the possible factors making mucoadhesive hydrogels increase the
permeability of the loaded nanoparticles is that mucoadhesive hydrogels can open up the
tight junctions of the epithelium by dehydrating the cells as they swell 158. Given that the
nanoparticles were highly localized on the mucosa surface, the close contact of gel disk
and mucosa membrane might facilitate their transbuccal transport. The use of PEG-only
hydrogel resulted in a slightly higher degree of enhanced transbuccal delivery of
G4.5-AAF and PEG-G4.5 (AAF)-DPDPE, which was probably due to the rapid release
of those dendritic nanoparticles from the PEG-only hydrogel. However, PEG-only
hydrogels don’t have mucoadhesiveness and are not a suitable platform for preparation of
buccal administration formulations
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5.6

Conclusions
In summary, the transbuccal transport of CNS therapeutic dendritic nanoparticles

based on PAMAM dendrimer G4.5 was demonstrated. Functionalized PAMAM
dendrimer G4.5 displayed a higher permeability than the unmodified counterpart,
suggesting that dendrimer surface modification plays an important role determining
transbuccal permeation of dendritic nanoparticles. Transbuccal delivery of dendritic
nanoparticles was enhanced by permeation enhancer and gelatin/PEG sIPN. Future
studies include optimization of a buccal formulation based on gelatin/PEG sIPN loaded
with permeation enhancer, further elucidation of the impacts of size and surface
properties on the permeability of dendritic nanoparticles, and testing of pharmacokinetics
and pharmacodynamics (PK/PD) of therapeutic nanoparticles following buccal
administration. Given the high adaptability of PAMAM dendrimers, a wide range of CNS
drugs including therapeutic peptides, proteins, and genes will benefit from
dendrimer-based delivery and buccal administration.
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CHAPTER 6 CONCLUSIONS AND FUTURE DIRECTIONS

6.1

Conclusions
There are several intracellular barriers which affect gene transfection we

mentioned in the above chapters: cytotoxicity, cell uptake, endocytosis, endosome escape,
cytoplasm transport, polyplexes disassembly, nucleus entry, gene transcription and
expression. Amine-terminated PAMAM dendrimers have shown great promise for gene
delivery because of their high buffering capacity and numerous reactive surface groups
for biofunctionalization. Amine-terminated PAMAM dendrimers can package nucleic
acids tightly due to the presence of a densely charged surface, which is a desirable feature
for synthetic vectors. Nonetheless, it also makes the dendrimer-based polyplexes less
prone to unpacking following endosomal escape, thus impeding gene transport in the
cytoplasm and subsequent transcription.
In this dissertation, we designed and synthesized a series of gene and drug
delivery systems based on PAMAM dendrimers. We tried to explore several
functionalized non-viral gene vectors based on dendrimers regarding some of these
barriers. We used PEG-PDLLA to improve cytocompatibility of the dendrimer vector,
EGF for targeted cellular uptake by EGFR-expressing cells, and BAH linkage to enhance
the buffering capacity of the vector.
To overcome their potential toxicity, dendrimers are often surface modified with
biocompatible moieties such as PEG to a certain extent. PEGylation has been commonly
applied to reduce toxicity of dendrimers. Our previous work has demonstrated improved
cytocompatibility of PAMAM dendrimer modified with PEG-PDLLA. With regards to
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gene delivery, coating a shell of PEG-PDLLA onto the PAMAM dendrimer surface not
only made the vector biocompatible and biologically degradable to a certain extent via
hydrolysis of PDLLA ester linkages but triggered self-assembly of the modified
dendrimer into aggregates of larger sizes in aqueous solutions. A significant increase in
particle size allows plasmids to be encapsulated rather than complexed directly with
individual dendrimer molecules. Degradation of PDLLA blocks can potentially destablize
polyplexes to facilitate release of DNA plasmid from the vector. The incorporation of
PEG with low molecular weight (MW 1500) into the dendrimer enhanced the gene
transfection efficiency and the incorporation of PEG with high molecular weight (MW
6000 and MW 12000) into the dendrimer did not induce higher gene transfection
efficiency than unmodified dendrimer. 293T is a highly transfectable derivative of the
293 cell line into which the temperature sensitive gene for SV40 T-antigen was inserted.
According to the gene transfection studies in 293T cells using western blot, fluorescence
microscopy and flow cytometry assays, dendritic PEG-PDLLA with PEG MW1500 has
been shown to be capable of inducing higher GFP expression than unmodified
dendrimers, dendritic PEG-PDLLA with PEG MW6000 and dendritic PEG-PDLLA with
PEG MW12000. This work has demonstrated that the use of PEG-PDLLA to the
dendrimer helps cell compatibility and likely results in enhanced gene transfection. The
use of PEG-PDLLA to the dendrimer helps cell compatibility and results in enhanced
gene transfection. The transfection efficiency is dependent on chain length of
PEG-PDLLA. This new vector could be very useful in drug and gene delivery in future.
EGF-conjugated dendrimer nanoparticles, using a triglycine spacer for
conjugation of EGF were developed and they were further labeled with Qdots for
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fluorescence imaging study. Their uptake into cells with high EGFR expression was high
whereas uptake into cells lacking the receptor was low, indicating their intracellular
uptake is EGF receptor -dependent. EGF-dendrimer conjugates did not stimulate growth
of EGFR-expressing cells and just induced minimal stimulation of post-receptor signaling
pathways. Using delivery of vimentin shRNA plasmid and YFP siRNA, the efficiency of
nucleic acid delivery was demonstrated. The data indicate that EGF-conjugated
dendrimer nanoparticles may be a useful nanoscale vector for introduction of nucleic
acids or drugs into cells by a growth factor-targeted mechanism, and for targeted cell
imaging.
PEGylated PAMAM dendrimer G4.0 conjugates with bis-aryl hydrazone linkages
were synthesized, characterized and evaluated as a new gene delivery vector. The
buffering capacity of dendrimers was significantly enhanced with the incorporation of
bis-aryl hydrazone linkages in coupling of PEG. They could complex tightly with
plasmid DNA and displayed dramatically improved cytocompatibility. According to the
gene transfection studies, this new vector has been shown to be capable of both
transfecting more cells and inducing higher GFP expression than unmodified parent
dendrimer. This work has demonstrated that the use of bis-aryl hydrazone linkage helps
maintain or increase the buffering capacity of the functionalized dendrimer and results in
enhanced gene transfection. It can be used for future gene delivery study.
Functionalized PAMAM dendrimer as CNS therapeutic nanoparticles was
constructed using PAMAM dendrimer as the underlying carrier. Opioid peptide DPDPE
and transferrin receptor monoclonal antibody OX26 were successfully conjugated to the
dendrimer. The nanoparticles were labeled with fluoresceins. Their transbuccal capability
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were tested using a vertical Franz diffusion cell system mounted with porcine buccal
mucosa. Modified dendrimer displayed a higher permeability than the unmodified
counterpart, suggesting that dendrimer surface modification plays an important role
determining transbuccal permeation of dendritic nanoparticles. Also, coadministration of
bile salt sodium glycodeoxycholate (NaGDC) enhanced the permeability of dendritic
nanoparticles by multiple folds. Similarly, a multifold increase of permeability of
dendritic nanoparticles across the porcine buccal mucosal resulted from the application of
mucoadhesive gelatin/PEG semi-interpenetrating network (sIPN). These results indicate
that transbuccal delivery is a possible route for administration of CNS therapeutic
nanoparticles.
These vectors will be useful in gene and drug delivery and could be extended to
covalently conjugate other functional moieties for gene and drug delivery.
6.2

Future Directions
For gene delivery vectors G4.0-BAH-PEG42 and G3.0-PEG1500-PLA that we

developed, their transfection efficiency is still not satisfactory. How to further improve
their transfection efficiency still remains a topic of interest. Since PEI and polylysine are
well known for their outstanding gene transfection efficiency and high cytotoxicity, we
may conjugate them to low toxic PEGlylated dendrimers in order to achieve higher
transfection efficiency while reducing their cytotoxicity. In the future, we may design
multifunctional vectors based on dendrimers to overcome other extra- and intra-cellular
barriers for gene delivery with improved transfection efficiency. For example, design a
vector to enhance nuclear entry or to increase endosome escape efficiency.
For EGF conjugated dendrimers, we only tested one tumor cell line (HN12) from
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HNSCC. HN12 cells were established from a lymph node metastasis. In a previous study
in our lab, metastatic HN12 cells refractory to the stimulatory effects of EGF but showed
inhibition at higher growth factor concentrations during the proliferation assay

107

. In

another study, researchers synthesized and characterized FITC labeled dendrimer
G5-EGF conjugates

89

. They used them on primary HNSCC cells and found the

conjugates bound and internalized into several EGFR-expressing cell lines through a
receptor-mediated endocytosis way, similar to our findings. But the conjugates induced
EGFR phosphorylation and stimulated the cell growth to a greater degree than free EGF,
which are different from what we found on metastatic cell line HN12. In the future, we
may use other tumor cell lines such as primary HNSCC cell lines or lung cancer cells to
test our materials. Since HN4 cells are derived from a primary squamous carcinoma of
tongue in the same individual of HN12 cells, they may be a good point to start with for
our next step. We may use our materials to deliver other types of therapeutic nucleic
acids to cells such as p53 tumor suppressor gene and explore the best condition for their
usage. We can also apply them in vivo using tumor xenograft models.
For transbuccal delivery of CNS therapeutic nanoparticles project, we used frozen
porcine buccal mucosa for our permeability study. It is more piratical for us to use frozen
tissue instead of fresh buccal mucosa tissue due to the limitation regarding the slaughter
house. However, people may question that the frozen tissue may affect its integrity and
hence the permeability of the nanoparticles. In future we may explore the effects of
different storage conditions on the in vitro permeation of the nanoparticles across procine
buccal mucosa in the future. The storage conditions may include wrapped frozen in
aluminum, Phosphate-buffered saline with pH 7.4 at 4 centi-grade and Kreb’s
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bicarbonate ringer with pH 7.4 at 4 centi-grade at different times like 6h, 24, and 48 h.
Human buccal mucosa are nonkeratinized and with certain thickness, while the oral
mucosa of rats are keratinized and oral mucosa of dogs and monkeys are very thin. So
their buccal mucosa tissues are not suitable for our research. The buccal mucosa of
rabbits or pigs are non-keratinized and with certain thickness. While we can obtain
rabbits from the animal facility of our university but we can only obtain pigs from
slaughter houses, we may use rabbits instead of pigs in future. The major drawback of
buccal mucosa of rabbits is that their area is very small compared with that of pigs’.
Other future studies will include optimization of a buccal formulation based on
gelatin/PEG sIPN loaded with permeation enhancer, elucidation of the impact of size and
surface properties on the permeability of dendritic nanoparticles, and testing of
pharmacokinetics and pharmacodynamics (PK/PD) of therapeutic nanoparticles
following buccal administration in animal models.
Since our EGF conjugated dendrimers could be used for tumor treatment and
OX26 conjugated dendrimers could be used for brain targeted drug delivery, we can
design a new gene and or drug delivery system based on these functionalized dendrimers
and liposomes for brain tumor therapy. The blood-brain barrier (BBB) is a major obstacle
to brain drug delivery, including anti-tumor drug delivery. The BBB restricts nearly all
therapeutic water-soluble drugs to get into the central nervous system (CNS) while
lipid-soluble molecules can cross the BBB freely via diffusion. On one side, liposomes
are made of lipid layer so they can cross the BBB very easily and they have been used to
deliver hydrophobic or hydrophilic drugs to CNS. On the other side, transport systems
within BBB have been explored and many drug delivery systems have been developed
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based on ligand-receptor mediated transcytosis. OX26 can be used as a ligand for
transferrin receptors present on brain capillary endothelial cells within BBB. These
liposomes carrying brain-specific ligand may cross the BBB in significant amounts. After
crossing BBB, brain tumor-targeted EGF-conjugated dendrimers with anti-tumor drug
will be released from the liposomes and target brain tumor cells with specificity, as they
overexpress the EGFR at the cell surface. After we synthesize and characterize the novel
brain tumor-targeted liposomal drug delivery system, we can assess brain-targeting and
permeability ability of the liposomal drug delivery system in vitro and assess brain
tumor-targeting, anti-tumor proliferative ability and efficacy of the liposomal drug
delivery system in vitro and in vivo.
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